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ABSTRACT 
 
Patient compliance is a major factor in achieving optimal therapeutic outcomes. Pill burden, 
due to multiple drug therapies, has a great detrimental impact on compliance of the patient. 
Dose-dependent side-effects, associated with peak-trough plasma fluctuations of drugs, also 
have a negative impact on patient compliance with drug therapy. It is under these 
circumstances that zero-order drug release kinetics proves to be ideal. This is due to the lack 
of peak-trough fluctuations that occur with zero-order drug release, thereby minimizing the 
side-effects of drug therapy. Furthermore, a drug delivery system that may deliver more than 
one drug at a time may be beneficial to alleviate the pill burden associated with chronic 
diseases or specific health conditions. Novel drug delivery systems have been developed 
that offer zero-order or linear drug release.  Amongst such systems are multilayered tablets. 
However these systems generally offer the delivery of just one drug. The development of a 
delivery system that is able to deliver up to three drugs in a zero-order manner may prove to 
be significantly beneficial to greatly increase patient compliance and in turn therapeutic 
efficacy.  
 
The purpose of this study was to design a novel triple-layered tablet (TLT) matrix targeted at 
achieving stratified zero-order drug release. The central factor for the establishment of the 
TLT was the selection of ideal and novel polymers that are capable of acting as superior drug 
release matrices. Modified polyamide 6,10 (PA6,10) and salted-out poly(lactic-co-glycolic 
acid) (PLGA)  were employed as the outer drug-carrier matrices whereas poly(ethylene 
oxide) (PEO)  was used as the middle layer drug matrix. Specialized granulation techniques 
and direct compression were employed to prepare the TLT matrices.  Diphenhydramine HCl, 
ranitidine HCl and promethazine were chosen as model drugs for the study due to their 
similar high aqueous solubilities (100mg/mL). Matrix hardness, gel strength, swelling/erosion 
characteristics, Fourier Transform Infrared spectroscopy, Differential Scanning Calorimetry 
and in vitro drug release analysis employing High Performance Liquid Chromatography were 
performed on the TLT matrices in order to determine the physicomechanical and 
physicochemical nature of the TLT matrices. Computational molecular modeling (CMM) was 
employed to characterize the formation and dissolution of the TLT matrices. A box-Behnken 
experimental design was employed that resulted in the generation of 17 design formulations 
for ultimate optimization. In vivo animal studies were performed in the Large White Pig model 
to assess drug release behavior of the TLT. Ultra Performance Liquid Chromatography was 
employed for plasma sample analysis. 
 
The PA 6,10 layer provided relatively linear and controlled drug release patterns  with an 
undesirable  burst release  greater than 15%, which upon addition of sodium sulphate was 
greatly reduced. The addition of PEO to the salted-out PLGA layer greatly reduced the initial 
burst release that occurred when salted-out PLGA matrix was used alone. Desirable results 
were obtained from FTIR, hydration and swelling/erosion analysis. CMM elucidated the 
possible mechanism of zero-order release from respective layers. Upon completion of the 
Box-Behnken design analysis, an optimized TLT formulation was established according to 
the formulation responses selected namely the rate constants and correlation coefficients. 
The TLT displayed desirable near linear release of all three drugs simultaneously over 24 
hours, with approximately 10%, 50% and 90% of the drugs released in 1, 10 and 24  hours. 
An in vitro drug release comparison performed between the optimized TLT and the 
commercial tablets currently used, showed an unequivocal display of superiority of the TLT in 
terms of linear drug release over commercial tablets. A cardiovascular related drug regimen 
(Adco-simvastatin®, DISPRIN CV® and Tenormin 50®) was applied to the TLT to assess the 
flexibility of incorporating a range of drugs. The TLT furthermore provided near linear to 
linear release of the therapeutic regimen over 24 hours and maintained superiority over the 
commercial tablets. Benchtop Magnetic Resonance Imaging, porosity analysis and Scanning 
Electron Microscopy was utilized for further introspective characterization of the TLT. In vivo 
analysis demonstrated a definite control of drug release from the TLT as compared to 
commercial tablets which further confirmed the advantage of the TLT.  
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CHAPTER 1  
INTRODUCTION 
 
1.1. Background to the Study 
 
Patient compliance is a major influence of therapeutic outcomes, drug treatment regimens 
may become complex as they require the patient to take numerous tablets up to three or four 
times a day and this is therefore very influential to therapeutic results. In addition, a large 
number of conventional tablets need to be administered up to three or four times a day.  
Understandably, treatment regimens that require multiple drugs to be taken often can lead to 
non-compliance on the part of the patient (Townsend et al., 2003; Apu et al., 2009; Phutane 
et al., 2010; Shivaraj et al., 2010). This poses a significant problem as the majority of 
treatment available is in the form of oral drug delivery (Colombo et al., 2009) which is the 
most desirable route for drug delivery and is rapidly growing (Phutane et al., 2010). 
Decreased patient compliance to treatment regimens is always present and challenging 
(Vermeire et al., 2001), this is prevalent with chronic conditions. Non-compliance has proven 
to be a serious problem that poses significant financial disadvantages to healthcare.  
 
Pertinent to novel drug delivery technology is the concept of increasing patient compliance 
by endeavouring to simplify treatment regimens thereby improving treatment efficacy and 
therapeutic success. Developing Drug Delivery Systems (DDS) that reduce the number of 
tablets a patient is obliged to take is therefore very appropriate in this regard. Multilayered 
tablets that allow for sustained release of more than one drug at a time have been proven to 
be useful in addressing this issue (Kohlrausch, 2005).  
 
The current standard, regarding conventional drug therapy, is first-order drug release. Most 
of the available drug products administered by and to patients exhibit first-order drug release 
kinetics. With first-order kinetics, there is a rapid disintegration of the tablet almost complete 
release of the drug active within 2 hours of administration. This results in initial elevated 
plasma levels of the drug after administration, followed by an exponential decrease. This 
poses a disadvantage as there will be minimal therapeutic efficacy after drug levels drop to a 
certain amount or drug toxicity at very high plasma levels (Landgraf et al., 2005). This type of 
drug release does not allow for appropriate plasma drug level balance. Peak-to-trough 
fluctuations may occur with first-order drug release that can cause dose-dependent side-
effects (Shahiwala et al., 2004). This is poses a significant impediment that may result in a 
lack of patient compliance with the treatment regimen due to the side-effects that are 
associated with the peak-to-trough fluctuations.  
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Wherever applicable, a DDS should ideally exhibit zero-order drug release kinetics which 
allows for a constant quantity of drug to be released over an extended period of time 
resulting in uniform and sustained drug delivery (Ayres, 2004). Zero-order drug release can 
be used in antibiotic delivery, the treatment of hypertension, pain management, 
antidepressant delivery and numerous other conditions that require constant plasma drug 
levels (Landgraf et al., 2005). 
 
Multilayered tablets have been developed or patented for simplifying various treatment 
regimens. For example, a bilayered tablet containing a statin and aspirin for the treatment of 
cholesterol and reducing the risk of a myocardial infarction was developed (Ullah et al., 
1998). The tablet was comprised of two layers, one containing aspirin and the other 
containing a statin. The proposed function of the tablet was to minimise the interaction 
between the two drugs (Ullah et al., 1998). However the drug release kinetics achieved from 
the tablet did not follow zero-order. 
 
There are several challenges that are associated with achieving zero-order drug release from 
the outer layers of a multilayered tablet. The outer layers are able to delay the interaction of 
the inner layer with the liquid medium by reducing the surface area available for release of 
the drug and by decreasing the penetration rate of the solvent (Efentakis et al., 2006). This 
results in zero-order drug release from the inner layer. The outer layers therefore are more 
exposed to the gastrointestinal environment and more susceptible to changes and 
degradation. Control of drug release from the outer layers is therefore challenging. 
 
A coated platform-delivering tablet is described in a patent (Ayres, 2004, US Patent 
6720005). Osmotic pumps are very good at providing zero-order drug release; the tablet had 
a rigid coating membrane. A laser was used to form a hole (aperture) through the coating. 
The tablets presented a lag time of approximately 2 hours prior to drug release due to the 
time taken for the gastrointestinal fluids to penetrate the semi-permeable coating membrane. 
This device has been widely used in providing zero- order drug release. However, there are 
challenges with large scale manufacturing and specialised laser equipment is needed to drill 
holes through the coating layer. There are various other problems associated with drug 
delivery from osmotic tablets such as cost of manufacture (Dash and Cudworth ll, 1998; 
Kaushal and Garg, 2003; Ghosh and Ghosh, 2011). 
 
Central to achieving zero-order kinetics with a DDS is the intimate selection of suitable 
polymeric material. There are various polymeric materials that have shown the ability to 
control the release of drugs (Peppas, 1997). Examples of these include poly(lactide-co-
glycolide) (PLGA) which is biodegradable, polyethylene oxide (PEO) which is robust and 
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swells, HPMC and poly(acrylic acid) (PAA) which is hydrophilic (Jian-Hwa Guo,copyright 
2001-2007). Studies have shown that the main factors affecting the release of drugs are the 
geometry of the tablet, the polymers used, as well as method of formulation (Varma et al., 
2004). The suitable use of these polymers as drug carrier matrices is an essential aspect of 
controlled drug delivery. 
 
Therefore the aim of this study was to develop a triple-layered tablet (TLT) containing drug in 
each polymeric layer with drug release from each layer ideally following zero-order kinetics. 
Each layer will contain one drug, therefore offering the delivery of up to three different drugs. 
The use of polymers such as PEO, HPMC and PLGA amongst other specialised polymers 
capable of providing zero-order drug release was explored for use in the design of the drug 
delivery system. 
 
1.2. Rationale and Motivation for this Study 
 
Chronic conditions such as hypertension, tuberculosis, HIV and malaria require multiple drug 
therapy. Adherence to therapy in these conditions by patients can be tedious therefore the 
TLT system may also be used to deliver drugs in a zero-order fashion all in a single dose 
with significant potential to reduce the associated dose-dependent side-effects that are 
caused by peak-to-trough fluctuations. The delivery of antidepressants may possibly also be 
incorporated into the TLT to provide superior plasma drug level profiles as well as reduced 
daily doses. Figure 1.1 illustrates the peak-to-trough fluctuations associated with general 
drug administration and the effect of zero-order drug release kinetics on these peak-to-trough 
fluctuations.  
 
High blood pressure (hypertension) was the underlying cause of death for 56,561 Americans 
in 2006 and a primary or contributing cause of about 326,000 deaths. According to the South 
African Hypertensive Society, hypertension is prevalent in 1 in 5 adults. Hypertension is also 
a leading cause of death in adults aged over 55. Approximately 7 million people die every 
year due to cardiovascular related health conditions. In a recent South African Demographic 
and Health Survey, it was presented that 6.1 million South Africans have hypertension or are 
taking antihypertensive medication.  
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Figure 1.1: Schematic diagram demonstrating peak-to-trough fluctuations and the effect of 
zero-order drug release on plasma drug concentration. 
 
Current multilayered drug delivery systems do not offer the flexibility of the delivery of three 
drugs in a zero-order manner. Various studies have revealed the development of 
multilayered tablet devices for modified drug release. The limitation however is that 
essentially, most of the systems developed allow for the controlled release of one drug only. 
This usually occurs from the middle drug loaded layer.  
 
Hence, this study proposes a DDS, a polymeric triple layered tablet (TLT) for stratified zero-
order drug release that will desirably lead to better therapeutic outcomes and increase 
patient compliance through overcoming the challenges associated with multiple drug 
treatment regimens. The main mechanism to achieve this would be providing sustained or 
controlled zero-order drug release. In comparison with other multilayered oral drug delivery 
systems that have been developed, the TLT would offer zero-order drug release from up to 
three tablet layers. 
 
The aim of this study was to therefore develop a polymeric TLT that offers stratified zero-
order drug release for potential use in the treatment of chronic conditions that require 
multiple drugs to be delivered in a zero-order manner. The TLT would be superiorly capable 
of improving plasma drug levels and allowing the incorporation of up to three drugs in a 
single DDS to enhance patient compliance.  
 
The uniform dosing that the TLT may offer would also help to reduce the side-effects 
associated with the drugs by reducing peak-to-trough fluctuations. In an attempt to provide 
superior control of drug release from the outer layers of the TLT, the drug in the outer layers 
were encapsulated into a polymer matrix using direct compression and specialised 
granulation techniques. The effects of modifying the geometry and chemistry of the outer 
layers of the TLT were essentially explored. The culmination of these factors was intended 
for the fundamental zero-order release of each drug.  Ideally when the TLT comes into 
Peak-to-trough plasma 
drug level fluctuations 
Effect of zero-order 
drug release on 
plasma drug 
concentrations 
Plasma 
Concentration 
Time 
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contact with the gastrointestinal environment the polymers will erode away or swell to release 
the drug. With polymeric matrices being the elementary backbone to the TLT formulations, 
various polymers or polymer combinations and specialized granulation techniques for 
example wet granulation were studied and utilized to aid in obtaining drug release in a zero-
order manner from the outer layers of the TLT.  
 
1.3. Novelty of the Proposed Triple-layered Tablet 
 
• The system offers zero-order release of up to three drugs in a stratified manner from 
………..a multilayered polymeric tablet. 
• Other multilayered systems that have been developed offer zero-order drug release 
………..from only one to two layers. 
• The use of newly synthesized polyamide 6,10 and salted-out PLGA as rate 
………..controlling polymers in the outer layers add to the novelty of the TLT. 
• The specialized granulation techniques and other approaches to achieve zero-order 
………..drug release from the outer layers enhance the novelty of the triple-layered tablet 
………..system. 
 
1.4. Aims and Objectives of the Study 
 
• Selection and synthesis of suitable polymers that may be employed as drug        
………..matrices for the outer layers of the proposed TLT. 
• To determine the physicochemical (e.g. structural molecular variations) and 
………..physicomechanical (e.g. hardness) properties of the polymers. 
• To develop a triple-layered tablet comprising formulation techniques such as 
………..specialised granulation approaches and direct compression. 
• To select suitable drug actives with a high water solubility (>50mg/ml) in order to 
………..prove the capability of controlled release of highly water soluble drugs. 
• To perform in vitro dissolution studies to determine the drug release kinetics. 
• To incorporate a therapeutic drug combination into the optimized TLT to assess the 
………..flexibility to control the release of various drug classes. 
• To perform in vivo animal studies to assess drug release kinetics and 
………..biocompatibility.of the TLT in a suitable animal model. 
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1.5. Overview of the Dissertation 
 
Chapter 1 introduces the challenges experienced in current drug therapies and emphasizes 
the rationale for the study. The aims and objectives of the study are also outlined in this 
Chapter. 
 
Chapter 2 provides a detailed description of the current and novel drug delivery 
developments in terms of geometrically modified oral tablet-like drug delivery systems such 
as multilayered tablets. It is a comprehensive literature review that outlines the fields of 
innovation involved in developing altered and superior tablet devices for oral drug delivery 
and the advantages and shortfalls of such devices. 
 
Chapter 3 contains the preliminary experimental laboratory formulation and development of 
a suitable feasible Triple-layered Tablet formulation. It outlines the formulation parameters, 
physicochemical and physicomechanical characterization, computational and molecular 
modelling and fundamental in vitro drug release analysis. 
 
Chapter 4 demonstrates the structuring of a Box-Behnken experimental design which 
involved the selection of suitable formulation responses and complex in vitro drug release 
analysis and the statistical optimization of the Triple-layered Tablet.  
 
Chapter 5 exhibits the further essential physicomechanical analysis such as porosity 
analysis, Scanning Electron Microscopy imaging and Magnetic Resonance Imaging that was 
performed on the optimized TLT. The additional incorporation of a therapeutic drug regimen 
into the optimized Triple-layered Tablet is also assessed and comparative analysis with 
conventional products is demonstrated. 
 
Chapter 6 is an inclusive analysis of the in vivo drug release testing in the Large White pig 
model. The establishment of a suitable protocol for the administration of the Triple-layered 
Tablet and blood sampling is also presented. 
 
Chapter 7 provides the conclusions for this study and recommendations for future work. 
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CHAPTER 2  
REVIEW OF ORAL DRUG DELIVERY SYSTEMS COMPRISING ALTERED GEOMETRIC 
CONFIGURATIONS FOR CONTROLLED DRUG DELIVERY 
 
2.1. Introduction 
 
Modified or controlled release oral drug delivery systems have over the few decades been 
shown to offer advantages over the conventional methods (Deshpande, 1996; Green, 1996; 
Rubinstein et al., 2007; Abdul and Poddar, 2004; Yu et al., 2009). These include increased 
patient compliance (Chien, 1982; Wilding et al., 1991), selective pharmacological action; 
reduced side-effect profile and reduced dosing frequency (Fassihi et al., 1995). These 
systems may therefore have a significantly beneficial outcome in therapeutic efficacy. 
Controlled release offers prolonged delivery of drugs and maintenance of plasma levels to 
within a therapeutic range (Singh, 2000; Lingam et al., 2006). Furthermore, by pairing drug 
administration rate with drug elimination rate, steady-state plasma levels can be maintained 
(Shah et al., 1988; Hardy et al., 2007). Currently most drug delivery systems exhibit first-
order drug release kinetics where the plasma level of the drug is extremely high after 
administration and then decreases exponentially. This poses disadvantages such as minimal 
therapeutic efficacy due to reduced drug levels; or drug toxicity which can occur at high 
concentrations (Landgraf et al., 2005). This type of drug release does not allow for 
appropriate plasma drug level balance.  
 
The utilization of geometric principles has been considered and employed in order to modify 
drug release behavior from non-linear to zero-order or near zero-order release kinetics 
(Brooke et al., 1977; Ford et al., 1987; Sangalli et al., 1993; Siepmann et al., 2000; Wise, 
2000; Cobby et al., 2006, Sakamoto et al., 2010). Thus far researchers have attempted to 
control dissolution behavior of drug delivery systems by modifying and controlling the 
geometry of the employed devices e.g. geometries such as spherical, cylindrical, holed 
cylindrical and biconvex devices were developed and investigated (Cao et al., 2001; 
Karasulu et al., 2003; Efentakis and Politis, 2006; Martin del Valle et al., 2009). 
 
One of the principles involved in altering the geometry of tablets is to create a constant 
surface area for drug release to enable the achievement of zero-order kinetics (Sundy et al., 
2004; Dash et al., 2010). Systems such as multilayered tablets, donut-shaped tablets, 
Procise®, Geomatrix® and Smartrix® technologies have been developed employing geometric 
manipulations (Conte et al., 1993; Kim, 1999; Wise, 2000; Efentakis, 2006; Yu et al., 2009). 
These geometric manipulations may also be employed to develop drug delivery systems for 
the treatment of specialized biological conditions where zero-order drug release is not 
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optimal, for example chronotherapy for heart conditions (Survase et al., 2007) or the 
scheduled treatment of asthma and inflammation (Losi et al., 2006). Bimodal drug release 
may also be desirable with drugs that have variable absorption sites along the gastro-
intestinal tract (Shah, 1988; Gohel et al., 2009). Technologies such as the Dome Matrix® 
have shown promise in achieving varied drug release profiles in order to treat specific 
conditions (Losi et al., 2006). Dilacor XR™ was developed as an extended release 
formulation for the delivery of diltiazem hydrochloride as described by Colombo and co-
workers (2000) where the geometry of the system played an important role in the release 
profiles of drugs (Colombo et al., 1989). 
 
In addition, the polymeric materials used to construct these technologies play an important 
role in the functioning of these specialised systems (Efentakis, 2006; Martin del Valle et al., 
2009). Thus far, various types of polymers have been investigated for their ability to control 
drug release (Brannon-Peppas, 1997; Bernkop-Schnurch et al., 2003; Jones, 2004; Yoo et 
al., 2006; Song et al., 2009).  
 
Polymers are the essential drug carriers of multilayered matrix tablets (Efentakis et al., 2006) 
and their properties are an important factor in the behavior of these devices. In the past, 
polymers that were mainly employed for such purposes were the hydro-polymers (Efentakis 
et al., 2006) while currently the employed polymers range from swollen and non-swollen 
(Jones, 2004; Efentakis et al., 2006; Herrlich et al., 2009) porous and non-porous (Mueller 
and Heiber, 1983; Crotts and Park, 1995; Learoyd et al., 2009) to erodible or non-erodible 
polymers (Brannon-Peppas, 1997; Naveen, 2009; Yu et al., 2009).  
 
In general, the mechanisms by which polymers perform their functions are by erosion (Heller, 
1987), dissolution and swelling (Harland et al., 1988). Some studies have shown that drug 
release from hydrophilic polymer matrices exhibit a typical time-dependent profile for which 
the drug release becomes controlled after swelling of the polymer (Lee et al., 1985; Nelson et 
al., 1987; Peppas et al., 1989; Wilding et al., 1991; Narasimhan et al., 1997; Conte et al., 
2000).  
 
This chapter thus discusses the application of altered geometric technology and its role in 
controlled oral drug delivery, focusing primarily on the types of polymers that have been 
employed in developing geometrically modified systems, the interplay of system geometry 
and polymeric selection ultimately contributing to the type of drug release patterns that are 
attained. 
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2.2. Multilayered Tablets for Controlled Drug Delivery 
 
Mutilayered systems (bilayered, triple-layered or quadruple-layered) are becoming 
increasingly recognised as controlled-release drug delivery systems (Yang et al., 1997; 
Zerbe et al., 2006). These systems have shown to be advantageous over typical tablet 
systems as depicted in Table 2.1.  Namdeo (2008) expressed that multilayered tablets have 
demonstrated promise, possessing various benefits namely the ability to prevent interactions 
between drugs and excipients; providing an array of release profiles in one delivery system 
of either the same or different drugs; treatment for conditions that require a regimen of more 
than one drug; immediate drug release using a disintegrating monolithic matrix in order to 
achieve an initial peak in plasma drug level; delayed drug release using an eroding 
monolithic matrix which may deliver another active to another part of the gastrointestinal 
tract; providing controlled drug release using a swellable monolithic matrix; provide better 
control and regulation of release profiles by retarding initial burst release and providing zero-
order kinetics (Namdeo, 2008).  
 
The advantages make it apparent that multilayered tablets may play a significant role in 
future drug delivery trends due to the various capabilities they pose over conventional 
systems. It would be beneficial to focus on further modification of these systems for more 
improved and comprehensive drug release control that is capable of a larger scope of 
application in drug delivery.  
 
Controlled-release multilayered tablets typically involve a drug core layer that is surrounded 
by barrier layers that may be made up of hydrophilic swellable polymers such as 
hydroxypropylmethylcellulose (HPMC) and poly(ethylene oxide) (PEO) or hydrophobic 
polymers such as ethylcellulose (EC) (Abdul et al., 2004.). The barrier layers minimize and 
therefore delay the interaction of the gastrointestinal environment with the active core, by 
decreasing the surface area available for drug release or by controlling the rate at which the 
solvent penetrates the layers (Efentakis et al., 2006). This allows the initial burst release to 
be minimized and therefore the drug release can be controlled at a near constant level while 
the barrier layers undergo erosion or swelling (Brannon-Peppas, 1997; Yu et al., 2009). The 
swollen barrier layers undergo erosion as time goes on, thus increasing the surface area 
which ultimately allows more drug to be released. Following the same principle it is possible 
to obtain a constant release profile as well as other types of dissolution patterns such as 
pulsatile or delayed delivery as well as extended drug delivery depending on the 
characteristics of the polymers employed. In either case the system should ideally erode 
completely (i.e. leaving no residue in the gastrointestinal tract after the entire amount of drug 
is released).  
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Table 2.1: Advantages of Multi-layered tablets over conventional tablets (Adapted from 
Namdeo, 2008).    
Conventional tablet Multilayered matrix tablets 
 
 
Drug is released in only one kinetic model. May be used to incorporate more than one drug 
and separate them if any chemical 
incompatibilities exist. 
 
If more than one drug is incorporated, there is 
no way of avoiding chemical incompatibilities. 
 
Drug release behavior is not restricted to one 
type, this system may offer varied drug release 
kinetics of the same or different drugs such as 
extended and immediate release. 
 
 
The different types of multilayered tablets designs with varying drug release behavior are 
shown in Figure 2.1.  
 
 
Figure 2.1: Various polymeric formulations of multilayered tablets and possible drug release 
behavior (adapted from Chidambaram et al., 1998). 
 
There are multilayered tablets that can provide zero-order sustained release where the tablet 
consists of either a hydrophilic or hydrophobic core layer with barrier layers that are press 
coated to the surfaces of the core layer. This leaves the sides of the core layer exposed. It 
Hydrophobic 
polymeric 
barrier layers 
Hydrophilic 
polymeric 
barrier layer 
swells after 
infiltration of 
medium 
Hydrophilic 
swellable 
drug matrix 
core 
 
Zero-order  
drug release 
Dissolution 
Medium 
Hydrophobic 
drug matrix 
core 
Non-linear 
drug release 
Geomatrix® 
Hydrophobic 
drug matrix 
core 
Hydrophobic 
drug matrix 
core 
d) 
b) 
a) c) 
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has been shown that, generally, constant drug release can be achieved when both barrier 
layers are hydrophilic and the core layer is hydrophobic (Qiu et al., 1998; Abdul et al., 2004). 
However, other factors also need to be controlled in order to achieve zero-order drug 
release.  
 
2.2.1. Geomatrix® multilayer tablet technology 
 
The Geomatrix® multilayer tablet technology was developed by Conte and co-workers (1993) 
for constant drug release. The technology includes triple-layered and bilayered tablets. The 
triple-layered tablet which is depicted in Figure 2.2 consists of an active core which is a 
hydrophilic matrix layer and two polymeric barrier layers on either side that are hydrophobic 
or semi permeable (Kim, 2005; Shionogi Pharma, 2008). The bilayered tablet consists of the 
drug layer and one barrier layer (Patel et al., 2007). The barrier layers modify the swelling 
rate of the active core and reduce the surface area available for diffusion of drug (Streubel et 
al., 2000; Efentakis and Peponaki, 2008). Zero-order drug release can be achieved with the 
Geomatrix® system (Yu et al., 2009) however release is limited to one drug. 
 
 
 
 
 
 
Figure 2.2: A typical Geomatrix® multilayered tablet (Source: Shionogi Pharma, Inc., 2008). 
 
2.2.2. Sodas® multilayer tablet technology 
 
Sodas® multilayer tablet technology (Figure 2.3) is a multilayer drug delivery system that has 
focused on the production of controlled release beads (Elan Drug Technologies, 2010). The 
Sodas® technology is characterized by its inherent flexibility that enables the production of 
customized dosage forms that respond directly to individual needs such as pain and blood 
pressure. The technology essentially leads a pursatile drug release where the drug is 
released in pulses that are separated by defined time intervals. Examples of this technology 
include Ritalin® LA and Focalin® XR. These formulations are both used to treat Attention 
Deficit Hyperactivity Disorder (ADHD). Furthermore, these formulations provide a once-daily 
pulsed profile that offers the patient efficacy throughout the day negating the need for taking 
the dose during working hours unlike the twice-daily dosing of the conventional immediate 
Barrier layers control the 
surface area diffusion of 
drug out of the core 
A core of HPMC 
matrix that 
contains the drug 
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release tablet. Benefits offered by the SODAS® technology include: controlled absorption 
with resultant reduction in peak-to-trough ratios, targeted release of the drug to specific areas 
within the gastrointestinal tract, absorption independent of the feeding state, suitability for 
use with one or more active drug candidates, a facility to produce combination dosage forms, 
“sprinkle dosing” by administrating the capsule contents with soft food, once or twice daily 
dose resembling multiple daily dose profiles. 
 
Figure 2.3: A schematic representation of Sodas® multilayer tablet technology (adapted from 
Elan drug technologies, 2010). 
 
The aforementioned studies have provided practical technical ideas in the development of 
multilayered tablets depending on the clinical applications of these systems. The studies 
have also provided insight on what strategies need to be considered for further application. 
Table 2.2 provides the summary of the polymers influencing the behavior and release 
characteristics of multilayered tablets. It is observed that there are great variations of 
multilayered tablet technologies proving flexibility, which affords possibilities for positive 
research betterment. With the intuitive selection of polymers and the appropriate employment 
of geometric principles, multilayered tablets may emerge as the future benchmark for the 
treatment of chronic diseases. However the difficulties that may occur with the scale up of 
more intricate layered drug delivery systems may present as unfavourable to the 
pharmaceutical industry. The necessity of specialized equipment may add to the difficulties in 
commercialization of these systems.  
 
Table 2.2: Summary of the type of polymers that influence the behavior and release 
characteristics of multilayered tablets. 
Type of polymer 
used  a drug carrier 
Type of polymer used 
in barrier layers 
Type/Dimensions of 
tablet 
Drug release 
achieved 
Hydrophilic Hydrophilic Bilayered Extended release 
Hydrophilc Hydophilic Bilayered Lesser extent of  
release retardation 
Hydophobic Hydrophilic (HPMC K4M) Triple-layered Zero-order release 
Hydrophobic (CW) Hydrophobic (CW) Triple-layered Non-linear release 
 
Protective coating 
Core granules or 
crystals 
Drug layer 
Release control  
Polymer-2 
Release control  
Polymer-1 
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2.3. Factors Influencing the Rate of Drug Release from Multilayered Tablets 
 
2.3.1. Polymers employed in multilayered tablets 
 
Generally, a multilayered system should initially swell, then gel and ultimately slowly erode 
(Abdul, 2004; Yang et al., 2003). A study done by Efentakis and co-workers (2006) 
investigated the effect of polymeric substances on drug release.  Hydrophilic and swellable 
polymers such as HPMC (Methocel K100M), microcrystalline cellulose (MC) and PEO and 
the hydrophobic polymer cellulose acetate propionate (CAP) were employed in this study in 
which venlafaxine HCl was used as a model drug. The study focused on a core tablet that 
contained venlafaxine HCl and Methocel K100M as the drug carrier. Bilayered and triple-
layered tablets were prepared using the core tablet. The bilayer tablet consisted of a core 
tablet where one surface was covered with either Cellulose Acetate Pthalate (CAP) or 
Methocel E50LV, while both surfaces of the core tablet were covered with both of the 
polymers to form the triple-layered tablets. Hydrophilic polymers are employed as drug core 
matrices due to their swelling ability (Hongtao et al., 2007; Conti et al., 2007; Li et al., 2008; 
Barakat et al., 2009).  The release profiles obtained showed that drug release was slower 
from the multilayered tablets than from the core tablet alone (Efentakis et al., 2006). When 
the core tablet came into contact with the dissolution medium, it swelled and expanded. This 
caused an increase in the diffusion path length for the drug and the drug release rate was 
therefore reduced. Upon employing HPMC as a barrier layer, the layer swelled concurrently 
with the core tablet, merging the core surfaces thereby enveloping part of the core, which 
resulted in the limiting of drug transport through the barriers (Efentakis et al., 2006). CAP did 
not swell due to its impermeability properties and therefore drug dissolution and the drug 
release rate was retarded. The use of HPMC or CAP in the barrier layers showed similar 
results in terms of retarding drug release except that HPMC showed slow erosion as 
opposed to CAP (Efentakis et al., 2006). HPMC devices, generally, presented with slower 
drug release when compared to CAP devices, reason being that they form a more efficient 
and solid barrier. Overall, the study showed that the characteristics of the polymers 
employed had a significant influence on the release profiles of the tablets although the choice 
of polymers employed in the study was conservative. Further research that focuses on the 
use of novel specialised polymers that are competent in providing zero-order drug release is 
necessitated. 
 
A study performed by Chidambaram and co-workers (1997) assessed the behavior of 
layered diffusional matrices for zero-order sustained drug release. Layered tablets were 
formulated with a hydrophobic core layer which contained the drug; this layer typically 
consisted of 24% pseudoephedrine HCl, 40% carnauba wax and lactose filler. The barrier 
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layers were composed of either hydrophilic (HPMC K4M or K100M or microcrystalline 
cellulose (MCC) PH 101) or hydrophobic polymers. Three different types of matrices were 
formulated. In the first type, the two barrier layers were hydrophilic, in the second type, one 
of the barriers was hydrophobic while the other was hydrophilic and in the third type, the two 
barrier layers were both hydrophobic. Results showed that more desirable linear release 
profiles were obtained with the first and second type of matrices as depicted in Figure 2a and 
d, while the barrier layers in the third system needed to be manipulated in order to achieve 
zero-order release kinetics (Chidambaram et al., 1997; Qui et al., 1998). The proposed 
mechanism for the zero-order drug release from the first type of matrix was that as the 
hydrophilic barriers swelled and eroded the rate of diffusion of drug from the hydrophobic 
middle layer decreased (Chidambaram et al., 1997; Yang et al., 1998). According to the 
study, the release rate from the lateral surface was influenced by polymer viscosity and 
concentration. These factors ultimately influence diffusion path length as well as the diffusion 
co-efficient. The use of polymers that possess mechanical or chemical characteristics to 
intrinsically alter the geometry, via modification of diffusion path length, of matrices for 
controlled release may be an interesting perspective to study for future drug delivery 
research. 
 
2.3.2. Structure of the multilayered tablet device 
 
A study undertaken by Efentakis and co-workers (2006) illustrated that the structure of a 
DDS plays an important role in its drug release behavior. They found that covering a greater 
area of the core tablet by a barrier layer results in the retardation of drug release to a greater 
extent, as it forms a more efficient barrier thereby decreasing the drug release rate. Another 
study by Efentakis and Peponaki (2008) re-iterated the significance of structure and 
geometry of triple-layered tablets with isosorbide mononitrate as a model drug. The weight 
and thickness of the barrier layers also had a role in drug release behavior. Chidambaram 
and co-workers (1997) established that drug release from the surfaces of the core was 
dependent on the thickness of the hydrophilic barrier layers. An investigation by Streubel and 
co-workers (2000) looked at bimodal drug release from multilayered matrix tablets. It was 
discovered that by increasing the weight of the barrier layers from 50mg to 150mg it resulted 
in a more effective retardation of drug release, thus it was concluded that by manipulating the 
weight and thickness of the outer layers (Table 2.2) a desirable drug release profile of 
individual drugs may be achieved, thus complementing their pharmacokinetic behavior. The 
concept of barrier layers have proven to be beneficial in multilayered tablet designs however 
converting the barrier layers into additional controlled release drug matrices may prove to be 
beneficial for future application (Namdeo, 2008). 
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Zerbe and co-workers (2006) have shown that there are also complex multilayered tablet 
systems with layers of various shapes that are able to provide zero-order drug release. The 
Smartrix® tablet technology (Figure 2.3) that was developed by LTS Lohmann Therapie-
Systeme employs modified geometrical shapes that compensate for the varying surface area 
caused by erosion or swelling (Table 2.3) (Rathbone et al., 2002).  
 
The triple-layered tablet is composed of a drug core that has a specific shape. The core is 
enclosed between two rapidly erodible outer layers. The middle layer has a biconcave shape 
that the two outer layers tightly bond to after compression. The thickness of the outer layers 
and the shape of the drug core control the release of drug usually in a linear fashion. The 
Smartrix® system (as depicted in Figure 2.4) is also able to achieve bimodal drug release 
(Porter, 2009) as an added advantage of being flexible. This technology proves to be useful 
as it does not require specialised polymers to perform the desired function. The study that 
resulted in the development of the Smartrix® system has further emphasized the functionality 
of shape and geometry in altering drug release behavior and the research has demonstrated 
favourable outcomes. However this technology requires specialized dry tablet press 
machines that may pose as a disadvantage. 
 
 
Figure 2.4: Smartrix® technology (Adapted from Rathbone et al., 2002).  
 
2.4. Bilayered Tablets 
 
Bilayered tablets have proven to be effective in delivering drugs that require a loading dose 
followed by a maintenance dose (Doshi et al., 2007; Patra et al., 2007; Nirmal et al., 2008; 
Kim et al., 2008). Commonly, in bilayered systems, one layer contains a quantity of drug for 
conferring immediate release, while the second layer contains a quantity of drug for extended 
release. The rapid release layer disintegrates immediately after administration while the 
matrix layer remains intact during the passage of drug through the gastrointestinal tract. The 
matrix erodes in a controlled fashion in order to maintain blood levels. Two drugs may also 
be incorporated into this delivery system for variable release profiles. 
Rapidly eroding outer layer 
Drug released from altered shape layer in a 
linear fashion as the outer layers rapidly erode 
Geometrically altered drug core layer 
Rapidly eroding outer layer 
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A bilayered tablet for the delivery of propranolol hydrochloride was developed by Patra and 
co-workers (2007). These tablets were comprised of an immediate release layer and a 
sustained release layer. Sodium starch glycolate was employed as the superdisintegrant in 
the rapid release layers of various formulations, while the polymers Eudragit RLPO, Eudragit 
RSPO and EC were utilised in the sustained release layers. Drug release studies illustrated 
that there was an initial burst release that delivered the loading dose while the rest of the 
drug was released over 12 hours in a sustained manner (Patra et al., 2007). The same 
concept has been demonstrated in a patent by Kim and co-workers (2008) where the system 
provided release of two drugs in different manners. The controlled release layer delivers 
metformin while the rapid release layer delivers glimepiride. The controlled release layer is 
made up of a mixture of hydrophobic and hydrophilic polymers, while the immediate release 
layer is composed of a disintegrant and glimepiride. This further enhances the positive 
function of these systems in treating chronic conditions such as hypertension and diabetes.  
 
Nirmal and co-workers (2008) developed a bilayered tablet containing atorvastatin calcium 
for immediate release and nicotinic acid for extended release for the concurrent treatment of 
hypercholesterolemia. It has been shown that the combination of these two drugs results in 
an important reduction of low density lipoprotein cholesterol as well as desirable variations in 
high density lipoprotein cholesterol (Nirmal et al., 2008). HPMC K100M was employed as the 
polymeric matrix for nicotinic acid and the immediate release layer containing atorvastatin 
calcium was formulated using superdisintegrant croscarmellose sodium. Drug release 
studies were performed over 12 hours and the results indicated that these tablets were 
successful in delivering two types of drugs concurrently (Nirmal et al., 2008). This study was 
shown to be valuable for future application in the successful treatment of hypertension. 
 
2.4.1 VersaTab® bilayered tablet technology 
 
A VersaTab® bilayered tablet technology is a tablet that has been devised to result in linear 
drug release through controlled erosion (IntelGenx Corp, 2009). The technology designs 
tablets with the ability to co-release multiple drugs with different release rates. This 
technology is suitable for a large number of bioactives. The tablet is highly versatile with a 
broad range of delivery profiles and therefore endowed with improved patient compliance. 
Figure 2.5 displays a profile that depicts VersaTab® bilayered tablet technology firstly with 
one bioactive that provides controlled release and secondly with two bioactives that provides 
immediate release and controlled release (IntelGenx Corp, 2009). 
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Figure 2.5: a) VersaTab® bilayered tablet; Profiles depicting VersaTab® bilayered tablet 
technology; b) One bioactive-controlled release and c) Two bioactives-immediate release 
and controlled release (Sourced from: IntelGenx Corp, Innovative Drug Delivery Solutions, 
2009). 
 
2.5. Triple-layered Tablets 
 
Triple-layered tablets are comprised of an inner drug core layer which is sandwiched 
between two surrounding barrier layers (Abdul, 2004; Namdeo, 2008). These barrier layers 
may also contain drug and serve as matrices to release drug in various release patterns 
(Namdeo, 2008). The general mechanisms of action of triple-layered tablets include erosion 
of matrix layers, creation of a drug concentration gradient, limiting surface area of release of 
the swellable matrix by the barrier layers, erosion and swelling of the barrier layers to 
achieve a constant area for uniform drug release, as well as modification of the layers 
dissolution to achieve pulsatile or alternating release profiles (Efentakis, 2006; Namdeo, 
2008).  
 
Triple-layered systems have some rewards in contrast to typical systems due to the varying 
release pattern capability, simplicity of manufacturing, enhanced patient compliance, 
enhanced safety profile of drug levels and reduced cost. 
 
2.5.1. GeolockTM technology 
 
GeolockTM Technology is a triple-layered tablet that has been devised for chronotherapy 
focused-real time oral drug delivery (SkyePharma, 2010). Principally, it is a new clinically oral 
drug delivery technology which allows, with a high degree of precision, the timed delivery of 
Drug core Polymer layers 
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drugs that employs a press-coating technique. GeolockTM tablet is composed of an active 
drug core (middle layer) that is surrounded by two outer protective layers (Figure 2.6). The 
inner core can be a single or combination of drugs essentially formulated for either 
immediate or modified release. 
 
Drug core
Polymer layers
 
Figure 2.6: A schematic of a triple layered GeolockTM tablet (Source: SkypePharma, 2010). 
 
2.5.2. Various drug release profiles achievable by triple-layered tablets 
 
It has been shown that both immediate and sustained drug delivery can be obtained through 
a single triple-layered tablet (Abdul, 2004). In this case, there is an initial immediate rapid 
release of drug, which is followed by a sustained constant drug release. This type of release 
could be useful for drugs that need a high plasma concentration immediately for therapeutic 
efficacy where zero-order drug release kinetics is not required. Maggi and co-workers (1997) 
developed such a system where a quick/slow release of Naproxen was achieved. A multi-
layered controlled release tablet containing naproxen and naproxen sodium salt was 
developed by Desai in 1996. The tablet composition included a layer containing naproxen 
which offered a delayed release of a granulated form of naproxen and another immediate 
release layer that contained naproxen sodium salt. This system was designed to deliver a 
prompt therapeutic effect while maintaining the effect for 24 hours (Desai, 1996). This type of 
variable release is extremely useful for the delivery of specific drugs that need both rapid and 
sustained release. A patent by Iyer and his co-workers (2006) reported on a triple-layered 
system that was comprised of a sustained release layer containing methylcobalamin while 
the other two immediate release layers each contained an antihypertensive, a lipid regulator 
or a serum homocysteine lowering agent providing a valuable combination for the treatment 
of hypertension. Compressed mini-tablets were designed for biphasic delivery of drugs with 
zero-order release kinetics (Lopes et al., 2006; Iyer et al., 2006). The mini-tablets were 
compressed within an outer filling that was composed of MCC PH102 that filled the space 
between the minitablets. This outer filling provided rapid drug release while the minitablets 
provided prolonged release (Iyer et al., 2006). The mini-tablets specifically were composed of 
either HPMC or EC, with a diameter of 2.5mm and an approximate weight of 12mg each. 
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Various formulations that differed in the amount of outer filling and number of mini-tablets 
used were prepared. Results showed that the mini-tablets with HPMC showed the most 
potential for achieving zero-order drug release. Another patent by Zerbe and co-workers 
(2004) presented a multilayer oral system that had a matrix core that contained an NSAID for 
sustained release and two surrounding layers each containing an H2–receptor antagonist. 
The first layer provided sustained release of the antagonist and the second layer provided a 
rapid release of the antagonist. This idea was developed for use in the treatment of 
osteoarthritis in people who are more susceptible to developing gastrointestinal adverse 
effects such as NSAID-induced ulcers. 
 
Time-programmed or chronotherapeutic drug delivery can also be achieved with multi-
layered tablets (Abdul et al., 2004). With chronotherapy, drug release is governed by time so 
that drug is released only when needed. This can be described as pulsatile release rather 
than continuous release. This type of delivery may be beneficial for preventing tolerance 
arising from the drug as well as in reducing the side-effects. Press coating is a good 
technique for producing this type of time-dependent release. With press coating, there are no 
specific coating solvents or equipment that is needed and therefore the manufacturing 
process is more efficient (Fukui et al., 2000). The core layer is essentially coated with 
polymeric barrier layers by compression. The drug is released when the barrier layers either 
swell or erode. The coating delays the interaction of the core with the fluid medium, which 
causes a lag-time before the drug is released. When the solvent penetrates the core layer, 
the core swells and dissolves, this causes the coating shell to break thereby rapidly releasing 
the drug (Abdul et al., 2004). This research further confirms the useful flexibility of triple-
layered tablets although the application is often limited to the release of one drug. 
 
It has been demonstrated that bimodal drug release may also be necessary when a non-
uniform drug release rate is desired (Streubel et al., 2000). The mechanism of release 
typically involves an initial rapid release, followed by a slower constant release, which is then 
followed by another rapid release period. Bimodal drug release may be advantageous in that 
the initial rapid release phase which is followed by a slow release phase is able to 
compensate for the slow absorption of drug from the stomach and small intestine. More 
uniform delivery of drug into the systemic circulation can be achieved because bimodal 
release systems increase the rate of drug release when the ability of the body to absorb the 
drug decreases. Streubel and co-workers (2000) developed multilayered matrix tablets that 
could achieve bimodal drug release rates. Hydroxypropylmethylcellulose acetate succinate 
(HPMCAS) was used to form the matrix due to the fact that its solubility varies with pH. It is in 
essence water soluble at high pH values and water-insoluble at low pH values. The study 
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aimed at determining the effect of HPMCAS on drug release from the different layers of the 
tablet. 
 
The various geometries of triple-layered tablets may be quite useful for controlling the 
delivery of highly water soluble drugs. A study by Siahi and co-workers (2005) investigated 
the development of triple-layered tablets for the delivery of verapamil hydrochloride in a 
controlled manner. The tablets consisted of three layers that were prepared by compressing 
polymers which were either natural or semi-synthetic onto the sides of the drug core. HPMC, 
acacia and tragacanth were used as drug release delaying layers encompassing the core. 
Different formulations containing separate and combined amounts of these polymers were 
prepared. The results indicated that when tragacanth was used as a carrier, the release was 
better delayed than when acacia was used. Results also showed that the location of the 
polymers in the triple-layered tablets had a substantial effect on the release kinetics.  
 
Triple-layer guar gum matrix tablet formulations were developed by Krishnaiah and co-
workers (2002) in which the controlled delivery of aqueous soluble drugs using guar gum as 
a carrier was explored. The system was evaluated in terms of the release rate of 
trimetazidine dihydrochloride from the matrix. Different concentrations of guar (30%w/w, 
40%w/w and 50%w/w) were used to prepare the triple-layered tablets. The guar gum acted as 
a release retardant agent. The release rate from these formulations enabled a twice daily 
administration of the delivery system (Krishnaiah et al., 2002).  
 
2.6. Multilayered Osmotic Devices  
 
An indented core tablet strategy for preparing monolithic osmotic pumps was developed by 
Longxiao and co-workers (2006). The tablet was compressed by a punch using a needle. 
The indented core was coated using EC as a semipermeable membrane coating and 
polyethylene glycol (PEG) was used as a plasticizer that controlled membrane permeability. 
The tablet was developed for the delivery of atenolol and sodium chloride and was used as 
an osmotic agent. Results showed that the tablet was capable of delivering the drug 
constantly over 24 hours and was not dependent on the agitation or release medium 
(Longxiao et al., 2006). This system does not require specialised laser drills to form the 
orifices, thus reducing manufacturing costs. The study was useful in attempting to develop a 
system that functioned as efficiently as an osmotic pump however in a more feasible and 
cost-effective manner. 
 
Longxiao and co-workers (2006) also prepared a bilayer osmotic pump tablet using the 
indented core strategy. The model drug used in the study was nifedipine. A modified tablet 
 21
punch was used to prepare the tablets whereby the punch formed an indentation in the 
centre of the drug surface layer. The indentation was sprayed with a coating solution with 
only the bottom of the indentation being sufficiently coated. The sides of the indentation were 
not completely coated, which left an aperture where drug release could occur (Longxiao et 
al., 2006). The tablet showed success in delivering nifedipine at a relatively constant rate for 
24 hours (Longxiao et al., 2006). 
 
The US patent RE 39069, by Faour and co-workers (1999), described a multilayered osmotic 
device that could deliver more than one pharmaceutical agent. The device was developed to 
deliver the first therapeutic agent by immediate release and the second in a controlled 
manner. Essentially, the device consisted of a core that contained a therapeutic agent, an 
osmotic agent and poly(vinylpyrrolidone) (PVP). The core was surrounded by a 
semipermeable membrane (as illustrated in Figure 2.7) that consisted of cellulose acetate 
esters and poly(ethylene glycol) (PEG) and contained a preformed passageway. The 
semipermeable membrane is essentially permeable to the dissolution environment and 
impermeable to the therapeutic agent in the core. The device was also coated with a 
poly(vinylpyrrolidone)-(vinyl acetate) copolymer that partially or completely surrounds the 
semipermeable membrane and covered the passageway like a plug. The final segment 
consisted of an external coat that was comprised of PVP and PEG and a second therapeutic 
agent that is immediately released. When the external coat releases the second agent, it 
erodes or dissolves thereby releasing the therapeutic agent that is contained in the core in a 
controlled manner. 
 
Figure 2.7: Schematic depiction of a multilayered osmotic device (Adapted from Fanner et 
al., 2005, US Patent 6838093). 
 
2.7. Multilayered Floatable Drug Delivery Systems 
 
A study that was conducted by Fassihi and co-workers (1995) looked at zero-order release 
kinetics from a self-correcting floatable asymmetric configuration drug delivery system. 
Theophylline was the model drug while PEO polymers of various molecular weights were 
employed as drug carriers. The various types of PEO polymers, drug and excipients were 
Passageway 
Core containing 
drug active 
Semi-permeable 
membrane 
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directly compressed into a triple-layer asymmetric floatable device. The core layer contained 
theophylline while the outer layers were composed of polymers and excipients in order to 
delay the interaction of the core layer with water, thereby delaying and controlling the drug 
release. Dissolution studies over 16 hours showed that the entire amount of drug was 
released in a zero-order manner with no initial burst release (Fassihi et al., 1995). The 
release was dependent on the thickness of the layers and polymers used. Fassihi and co-
workers (2007) also investigated zero-order delivery of alfuzolin hydrochloride via a 
gastroretentive system. Triple-layered and bilayered matrices were developed by 
compressing PEO, HPMC, sodium bicarbonate, citric acid and PVP. Dissolution studies 
demonstrated the ability of the matrices to achieve floatation in pH 2 and pH 6.8 as well as 
providing zero-order drug release (Fassihi et al., 2007). This system showed fine potential for 
providing enhanced bioavailability and targeted delivery to the small intestine. 
 
A study by Yang and co-workers (1999) proposed a drug delivery system that would be able 
to treat Helicobacter pylori-associated gastric ulcers. The system was comprised of a 
swellable, asymmetric triple-layered tablet that was also floatable so as to increase the 
gastric retention time of the system. The employed rate-controlling polymers were HPMC 
and PEO. The core layer of the triple-layered tablet contained the drugs tetracycline and 
metronidazole. In vitro studies exhibited a sustained delivery of the two drugs over 6-8 hours, 
while the tablet was retained, showing the potential to achieve localized treatment, thereby 
improving therapeutic efficacy. This study poses great potential for the essential eradication 
of the Helicobacter pylori infection that often results in hospitalization of patients who develop 
serious ulcers. 
 
A patent awarded to Doshi and co-workers (2007) described a floatable drug delivery system 
that is able to deliver multiple drugs. The system was bilayered and was able to deliver a 
drug from one layer immediately, followed by slow and controlled release of another drug 
from the other matrix-forming layer. The immediate release layer contained a disintegrating 
agent while the matrix-forming layer consisted of a gas generating component and a gelling 
agent (Doshi et al., 2007). The aim of this system was to attain a controlled delivery of 
fluoroquinolones and to maintain the plasma levels of the drugs within a therapeutic range 
with once daily administration. 
 
2.8. Core-In-Cup Devices  
 
Danckwerts (1994) developed a core-in-cup tablet system that was able to provide zero-
order drug release of aqueous-soluble and aqueous-insoluble drugs. The system consisted 
of a disc-shaped matrix core that was compression-coated on one surface as well as at the 
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circumference in order to form a cup around the core. Drug was released in a sustained 
manner from one stable surface that had a constant surface area. By manipulating the grade, 
quantity and exposed surface area of any hydrophilic polymer or mixture of polymers that 
erode constantly over time, the core-in-cup compressed tablet is able to deliver a constant 
amount of drug over time (Danckwerts, 1994). Results showed that the system was able to 
provide zero-order drug release for time intervals between 8 and 23 hours, the time of linear 
release was approximately 8 hours when 5%w/w HPMC K4M with caffeine core-in-cup tablets 
were produced and approximately 23 hours when 15%w/w HPMC K15M in ibuprofen core-in-
cup tablets were produced. The research that has been conducted on core-in-cup devices 
showed several interesting and useful techniques as well as beneficial application in terms of 
the solubility of drugs, the flexibility of delivering both aqueous soluble and aqueous insoluble 
drugs pose an advantage. Danckwerts and co-workers (1995) studied the effectiveness of 
cup tablets of different depths for use in core-in-cup tablets and the optimal formulation in 
terms of drug release behavior. They developed a specific punch that is able to change the 
depth of the cup tablet, thus allowing it to carry various cores in terms of hardness and mass. 
The efficiency of cup tablets with varying depths and the optimal formulation in terms of drug 
release were investigated in the study. The cup tablets were composed of 15%w/w carnauba 
wax in EC while the core tablets were composed of 5%w/w HPMC K4M in ibuprofen. The 
results indicated that Ibuprofen was released at a near zero-order rate for 18 hours for the 
cup tablets that had a final depth of 4mm (Danckwerts et al., 1995). Figure 2.8 shows the 
typical geometries of core-in-cup tablets. 
 
 
Figure 2.8: Typical geometries of core-in-cup tablets (Source: Guimarães et al., 2008). 
 
2.9. Procise® Technology 
 
The Procise® device has a specific geometric configuration (as depicted in Figure 2.5) that 
controls drug release behavior (Wise, 2000). It is composed of a core which contains 
uniformly dispersed drug with a core hole in the middle (Figure 2.9). It has been elucidated 
that altering the geometry of the core can vary the drug release kinetics to zero-order or even 
first order if desired (as indicated in Table 2.2) (Wise, 2000). The core’s entire surface 
besides the surface of the cylindrical face is surrounded by a permeable inactive coat so that 
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drug release occurs solely from the cylindrical area. The device is also able to deliver up to 
two drugs simultaneously with varying release profiles (Wise, 2000). This technology further 
adds to the varied geometrical systems for flexible and simplified drug delivery. 
 
 
 
Figure 2.9: a) Aerial schematic of Procise® technology and b) Two-dimensional schematic of 
Procise® technology (adapted from Porter, 2009). 
 
2.10. Donut-Shaped Devices for Controlled Drug Delivery 
 
There are various publications dating rather far back that established that zero-order release 
kinetics could be achieved from a hemispherical device containing a hole (Cleave, 1966; 
Rhine et al., 1980; Hsieh, 1983; Kim, 1995; Kim, 1999; Cheng, 1999; Sundy et al., 2004). A 
study by Kim (1995) investigated drug release from uncoated compressed tablets that 
contained a single central hole. The impact of the hole size and drug solubility on drug 
release was also investigated. The tablets were composed of PEO and had a diameter of 
12mm. Theophylline was used as the model drug. The tablets provided zero-order drug 
release for approximately 80-90% of the drug followed by a decreased drug release rate 
(Kim, 1995). The results also indicated that as the size of the hole increased, the rate of drug 
release also increased. Drug solubility proved to be inversely proportional to duration of 
linear drug release (Kim, 1995). It was concluded that the donut-shaped PEO tablets with an 
aperture were capable of providing zero-order drug release as the effect of surface area on 
release kinetics is reduced. The geometric factors that influence the drug delivery of donut-
shaped tablets are presented in Table 2.3.  
 
The hydrophilic polymer-based donut-shaped tablets developed by Kim (1995), exhibited a 
disadvantage as they adhered to biological tissues and solids causing dose dumping of the 
drug (Kim, 1999). It was due to this reason that Kim (1999), decided to undertake a study on 
coated donut-shaped tablets for parabolic and linear drug release. Two types of polymers 
namely rapidly erodible and slowly erodible polymers were investigated. Zero-order release 
was achieved when the slowly erodible polymers were used and parabolic drug release was 
achieved when rapidly erodible polymers were used when diltiazem hydrochloride was 
incorporated as a model drug. It was also found that the drug release characteristics 
depended on the stirring rate and hole size (Kim, 1999). These tablets did not adhere to 
Core 
surrounded 
by 
permeable 
coat 
Matrix core 
with a hole 
a) b) 
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either biological tissues or solids (Kim, 1999), thus proving to be more effective than the 
uncoated systems (Kim, 1999). Furthermore, HPMC donut-shaped tablets were developed 
and investigated by Cheng and co-workers (1999). Theophylline and diltiazem hydrochloride 
were employed as model drugs. Results depicted that zero-order kinetics was achieved for 
approximately 90% of the duration of the study (Cheng et al., 1999). An increase in the size 
of the centre hole caused an increase in the rate of drug release and a longer duration of 
zero-order release (Cheng et al., 1999). A further study was conducted by Kim (2005) on 
triple-layered donut-shaped tablets (Figure 2.10) with enteric polymers to evaluate their 
controlled release ability. The tablets were prepared by layering three powders and 
compressing them with a punch. HPMCAS was the fundamental polymer of the core while 
the outer layers were composed of EC. The results showed that the solubility of the drugs 
had an effect on release kinetics. The hydrochloride salts of weakly basic drugs had a slower 
release rate than neutral drugs (Kim, 2005). Thus, this system is capable of providing zero-
order drug release for drugs with varying solubilities.  
 
A study completed by Sundy and co-workers (2004) developed a novel compression-coated 
doughnut-shaped tablet for zero-order sustained release. The tablets were also assessed for 
their reproducibility. The tablets were prepared using a uniquely designed punch set. 
Hydrophilic and hydrophobic polymers were employed and evaluated as the coating layers. 
Caffeine and ibuprofen were used as model drugs as they have different solubilities and 
allowed for a comparison of the drug release profiles. Results showed that a coating layer of 
HPMC K15M and a core layer of HPMC K4M provided zero-order release of both caffeine 
and ibuprofen (Sundy et al., 2004). The tablets also proved to be feasible to manufacture on 
a larger scale. 
 
 
Figure 2.10: A schematic of a triple-layered, donut-shaped tablet (adapted from Kim et al., 
2005). 
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2.11. Dome Matrix® and “Release Modules Assemblage” Technology 
 
The dome matrix technology (described in Table 2.3) was developed by Losi and co-workers 
(2006). The elementary module (Figure 2.11a) is a swellable matrix device comprising of a 
concave base on one end and a convex base on the other end. Losi and co-workers (2006) 
also developed the “release modules assemblage” technology which implies the creation of 
different drug delivery systems, having various functions by the assemblage of two or more 
of the elementary/release modules. Figure 2.11 illustrates the dome matrix modules and 
examples of the possible assemblages that may be achieved. The drug release patterns 
from these assemblages depended on the manner in which the modules were placed or 
attached to each other (Losi et al., 2006). For example, multi-kinetics can be achieved and 
the delivery of two drugs in a single unit at a specific time and at a specific rate is also 
possible. Two types of assemblages were mentioned in this study; the first was called “piled 
configuration” (Figure 2.11c) where the convex base of one module is inserted into the 
concave base of another module and the second was called “void configuration” (Figure 
2.11b) where the concave base of one module is fixed onto the concave base of another 
module creating a space/void between the two modules (Losi et al., 2006). The modules 
were compared to flat base matrices in terms of drug release behavior. Buflomedyl pyridoxal 
phosphate (BPP) was the model drug used in the study. The results depicted that the 
modules did not completely alter the kinetics compared to flat base matrices having the same 
weight and composition. However, the dome matrix® had a higher initial release rate.  
 
                                  
Figure 2.11: a) Dome matrix® module, b) “void” configuration and c) “piled” configuration 
(Adapted from Losi et al., 2006). 
 
Convex base 
Concave base 
“Void” configuration: concave 
base-concave base 
“Piled” configuration: convex 
base-concave base 
Convex base of one module fits into the 
concave base of another 
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The concave and convex bases themselves exhibited different release patterns, with the 
convex base releasing drug faster (Losi et al., 2006). The technology proved to have 
potential benefits in terms of providing flexible drug release by increasing the amount of 
modules in an arrangement. This technology has various advantages although the 
complexity of the systems may be a shortcoming of the system in terms of administration of 
the devices to patients. A summary of various technologies that utilize geometric factors in 
drug delivery is provided in Table 2.3. 
 
Table 2.3: Summary of various technologies that utilize geometric  factors in drug delivery. 
Technology Design Factors affecting 
drug release 
Type of drug release 
Geomatrix® Triple/bi-layered tablet. Type of polymer, 
thickness of layers. 
Zero-order 
Smartrix® Triple-layered tablet with 
altered shape core layer 
Shape of core layer. Zero-order 
Procise® Uniformly dispersed drug 
core containing a hole. 
Geometry of core Zero-order 
Dome 
Matrix®/“Release 
modules 
assemblage” 
Various arrangements of 
elementary module 
containing a concave base 
and a convex base 
Arrangement of 
modules, type of 
polymer. 
Various according to 
arrangement of 
modules 
Core-in-cup 
devices 
Disc-shaped core 
compression coated on 
one surface and 
circumference to form a 
cup around it. 
Type of polymer, 
dimensions of core 
and cup. 
Zero-order 
Doughnut-
shaped tablets 
 
 
Single/triple-layered tablets 
with a central hole/holes 
Size and number of 
holes, type of polymer 
Zero-order 
Sodas® Multilayered tablet Type of polymer, 
thickness of layers. 
Shape of core layer 
Pulsatile release 
VersaTab® Bilayered tablet Core drug, polymer 
layers 
Immediate or 
controlled release 
GeolockTM Triple-layered tablet Polymer layers, single 
or combination of 
drugs in the inner 
core 
Immediate or modified 
release 
 
2.12. Concluding Remarks  
 
It has been elucidated that geometrically altered drug delivery systems especially 
multilayered tablets have provided various advantages to drug delivery technology. The ease 
of manufacture of these systems adds further benefit in terms of cost effectiveness.  These 
systems therefore show promise for therapeutic use in the future. The technology that these 
systems encapsulate, offers valuable knowledge and insight for the inspiration of more 
intricate and constructive drug delivery systems for wider applications. Future research may 
thus focus further on modifying these systems and using the basic technological principles to 
develop novel systems that could be applied in broader and more complicated drug delivery 
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such as in the treatment of more complex diseases with a larger drug regimen that requires 
more individualised types of drug release. With the appropriate selection of polymer matrices 
and specialised geometries, these systems could be used to deliver more drugs in a more 
controlled manner for adequate time periods. The fact that drug delivery systems with altered 
geometric configurations (particularly tablets) have shown promising results in drug delivery 
technology and the ease of manufacturing is an added advantage to the pharmaceutical 
industry. 
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CHAPTER 3  
FORMULATION, DEVELOPMENT AND CHARACTERIZATION OF NOVEL TRIPLE-
LAYERED TABLETS MATRICES FOR ZERO-ORDER DRUG RELEASE 
 
3.1. Introduction 
 
Essential to the construction of a Triple-Layered Tablet (TLT) is the consideration of factors 
necessary for achieving zero-order drug release from the outer layers. Studies that have 
been performed give testimony that it is possible to obtain zero order drug release from the 
middle layer of a multilayered tablet due to the uniform area of the exposed surfaces of the 
layer allowing for a constant release of drug (Efentakis et al., 2006), it is however difficult to 
achieve zero order drug release from the outer layers as the surface area per unit volume 
changes therefore causing changes in the diffusion resistances causing changes in the 
diffusion path length which changes the diffusion coefficient which changes the flux ultimately 
preventing constant amounts of drug to be released. The focus will therefore be on 
developing these outer layers to achieve the desired release kinetics. 
 
The basis for overcoming the challenges associated with the outer layer is the intimate 
selection of polymers based on their ability to control the rate of drug release by modifying 
the physicomechanical and physicochemical properties of the constituents and the geometry 
of the outer layers altering the diffusion and erosion kinetics which compensates for changes 
in surface area per unit volume resulting in uniform diffusion path lengths and uniform flux 
and hence, constant drug release. Polymers such as polyethylene oxide (PEO), PLGA and 
other specialised polymers will be assessed for use in the device.  
 
The novelty of the system lies in its potential ability to dramatically increase patient 
compliance by markedly simplifying treatment regimens and reducing side effects. The cost 
to produce such a system is reduced as the equipment required is cost effective and easy to 
acquire. This system will potentially have a beneficial outcome in treatment efficacy.  
 
The use of the Nylons in drug delivery has not been widely investigated. The Polyamides 
(Nylons) are materials that are mainly hydrophilic (Barringer et al., 1993) and erodible in 
nature (Kydonieus, 1999). These polymers are also hygroscopic (Bronzino, 2000); water 
attacks the amorphous regions affecting physical strength. 
 
A study by Torres et al. (1995) formulated microcapsules of a synthetic polyamide that 
contained ion-exchange resins employing the interfacial polymerization procedure. Sodium 
fluoresceinate was used as a resinate. In vitro release studies showed that the polymeric 
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coat of the polyamide delayed drug release. García-Encina et al. (1993) investigated 
polyamide-coated ion exchange resins containing sodium diclofenac. Drug release results 
indicated that this formulation provided a more controlled and sustained release of sodium 
diclofenac than from the commercial sustained release product of sodium diclofenac. 
Theophylline loaded gelispheres that were coated with an aliphatic polyamide was prepared 
by Vyas et al. (2000). Results showed that the coating was able to reduce the rate of drug 
release and control the rate of release in a pseudo zero-order pattern. 
 
Polyamide 6, 10 variants have been investigated for use in controlled drug delivery (Kolawole 
et al., 2007). Monolithic matrices comprising various variants of polyamide 6,10 were 
developed and evaluated in terms of drug release behaviour from the matrices. Three 
optimized variants were identified, namely the slow release, intermediate release and 
controlled release. The controlled release variant showed capability in providing zero-order 
release kinetics from a monolithic matrix. 
 
Poly (lactic-co-glycolic acid) (PLGA) has proven in several studies to be suitable for providing 
controlled drug release (Song et al., 1997; Pillay et al., 1999; Mittal et al., 2007; Corrigan et 
al., 2009) These polymers have a great advantage of being biodegradable (Peppas, 1997).  
Pillay et al. (1999) investigated electrolyte- induced heterogeneity as a novel approach to 
rate-controlled drug delivery. Swellable polymers, for example, hydroxypropylmethyllcellulose 
(HPMC) were used in conjunction with specific electrolytes such as sodium bicarbonate and 
pentasodium tripolyphosphate and formulated into monolithic drug delivery matrices. The 
results showed that zero-order drug release from these matrices was achievable. The 
electrolytes compete with the polymers for water hydration. 
 
Sibambo et al. (2008) performed a study on the development of salted-out PLGA scaffolds 
as monolithic drug delivery devices. The results showed that salting-out and crosslinking of 
PLGA modified the physicochemical properties of the original PLGA polymer thereby 
improving the potential for controlled drug release. The scaffolds showed excellent integrity 
in terms of structure and resilience. The bond formation in the PLGA backbone gives the 
scaffolds potential for providing zero-order release kinetics. 
 
This chapter investigates the use of these polymers as outer layer drug matrices for 
achieving zero-order release kinetics. According to the literature reviewed in Chapter 2, PEO 
has been shown to provide controlled drug release as a swellable hydrophilic matrix and was 
therefore employed as the middle drug matrix of the TLT. 
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Furthermore, it was decided that the model drug to be employed in the study was one that 
possessed a high aqueous solubility. The ability to provide controlled release of a highly 
aqueous soluble drug active from the outer layers would certainly be a beneficial 
achievement. This is due to the difficulty that this challenge poses (Sandile et al., 2006; Rao 
et al., 2010). This may be advantageous for treatment regimens containing three drugs, 
minimizing effort in the administration of medication and multiple doses to be compacted into 
one dose for maximal therapeutic efficacy. Hence, diphenhydramine (DPH) was the model 
drug selected for the study. DPH inherently possesses a high aqueous solubility 
(100mg/mL). 
 
Experimental studies involved the preparation of various TLT formulations, with either of the 
two novel aforementioned polymers employed as outer layer drug matrices. Drug release 
from these matrices was assessed. The effect of matrix hardness, swelling and erosion of 
the matrices on drug release behavior was also assessed. Differential scanning calorimetry 
was performed to determine the presence of chemical interactions between the various 
polymers as well as between the polymers and drug, the presence of drug may sometimes 
alter the thermal properties of polymers such as glass transition temperature which may have 
an effect on the mechanical properties of the polymer, thus affecting the functioning of the 
polymer in terms of drug release (Okhamafe et al., 1989; Wu et al., 1999; Nair et al., 2001).   
Fourier Transform Infrared Spectroscopy analysis was also carried out to determine any 
molecular variations of the polymers after compression and hydration.  
 
3.2. Materials and Methods 
 
3.2.1. Materials 
 
Hexamethylenediamine (HMD, Mw=116.2g/mol) was purchased from Merck Schuchardt 
(Hohenbrunn, Germany). Sebacoyl chloride (SC, 98%, Mw=239.1g/mol) was purchased from 
Sigma-Aldrich Co. (Aldrich, Steinheim, Germany), ethylcellulose (EC), diphenhydramine 
hydrochloride (DPH) was purchased from Sigma Chemical Company (St Louis, MO, USA). 
Polyethylene oxide (Polyox™ WSR 303) (PEO) was purchased from The Dow Chemical 
Company (Midland, MI, USA) and poly(lactic-co-glycolic acid) (PLGA, Resomer RG504 
50:50; Mw 48,000; i.v. 0.48-0.60dl/g) was purchased from Boehringer Ingelheim Pharma 
(Ingelheim, Germany). Sodium chloride, sodium sulphate, calcium chloride and zinc sulphate 
were purchased from Rochelle Chemicals (Johannesburg, South Africa). All other reagents 
used are of analytical grade and are used as purchased. 
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3.2.2. Methods 
 
3.2.2.1. Synthesis of modified polyamide 6,10 using a modified interfacial 
polymerization reaction 
 
The synthesis of polyamide 6,10 (PA6,10), involved the preparation of two solutions namely 
the aqueous phase and non-aqueous phase. HMD and sodium hydroxide (NaOH) were 
dissolved in de-ionised water (DW) to form the aqueous phase while the non-aqueous phase 
was composed of cyclohexane (C-HXN), hexane (HEX) and SC. Table 3.1 contains the 
quantities of constituents used in the two phases. The first solution was gradually added to 
the second to form two immiscible phases which resulted in a polymeric film being formed at 
the interface (i.e. by an interfacial polymerization process). The polymeric film was collected 
as a mass by slowly rotating a glass rod at the interface.  
 
Table 3.1: Quantities of constituents used in the synthesis of PA6,10 for controlled drug 
release. 
HMD(g) SC(mL) HEX(mL) DW(mL) C-HXN(mL) NaOH(g) 
1.75 0.20 40 10 10 0.4 
 
Upon collection of the polymeric mass, it was thoroughly washed with HXN to remove any 
un-reacted SC and then with DW (3×300mL) to remove any un-reacted NaOH. The 
polymeric mass was then lightly rolled on filter paper (diameter 110mm, pore size 20µm) to 
remove excess solvent and dried to a constant weight at 40°C over 48 hours. 
 
3.2.2.2. Synthesis of salted-out PLGA 
 
Synthesis involved the preparation of a polymeric solution and a salt solution. The polymeric 
solution was prepared by dissolving 400mg of PLGA 504 in 15mL of acetone and the salt 
solution was prepared by dissolving 1.15g of sodium chloride in 10mL de-ionized water. The 
polymeric solution was slowly added to 75mL of the salt solution while constantly stirring. 
The mixture was agitated on a magnetic stirrer for half an hour until a white mass of salted-
out PLGA (s-PLGA) was formed.  
 
3.2.2.3. Fourier Transform Infrared Spectroscopy analysis of components of the Triple-
Layered Tablet formulations for the determination of molecular variations after 
compression and hydration 
 
The native polymers, compressed polymers, compressed combinations of polymers and 
salts as well as hydrated samples were subjected to Fourier Transform Infrared (FTIR) 
analysis using a Perkin Elmer Spectrum 100 FT-IR Spectrophotometer (Massachusetts, 
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USA) in order to determine the presence of molecular structural variations that may have 
occurred after: i) compression of the polymers, ii) the combination of polymeric materials and 
iii) after hydration upon exposure to the dissolution medium. The consequences of the 
possible interactions on drug release from the matrices as well as possible interactions on 
drug release from the matrices were also evaluated.  
 
3.2.2.4. Differential Scanning Calorimetry and Alternating Differential Scanning 
Calorimetry analysis of polymeric material to characterize thermal behavior and 
determine the presence of polymer-polymer molecular interactions 
 
Differential Scanning Calorimetry (DSC) was carried out on native polymers, compressed 
polymers and compressed polymer combinations using a differential scanning calorimeter 
(Mettler Toledo, DSC1, STARe System, Swchwerzenback, Switzerland). Samples were 
weighed into aluminium pans and sealed. DSC thermograms were generated over wide 
temperature ranges at a rate of 10°C/min. Alternating differential scanning calorimetry 
(ADSC) was carried out on the samples at small temperature ranges depending on where 
thermal events occurred on the DSC thermograms at a rate of 1°C/min. Samples were 
assessed for potential chemical interactions that may have occurred at various temperatures 
by assessing changes in glass transition temperature (Tg) and melting points (Tm) of the 
polymers and the ultimate effect of these changes on drug release from the TLT. 
 
3.2.2.5. Preparation of TLT formulations 
 
TLT formulations as depicted in Figure 3.1 were prepared by direct compression using a 
Carver hydraulic press (Wabash, USA). PA6,10, s-PLGA and PEO were employed to 
comprise the three layers. Only one layer was loaded with drug at a time for the purpose of 
UV analysis. The effect of the addition of different salts namely sodium sulphate (NaSO4), 
calcium chloride (CaCl2) and zinc sulphate (ZnSO4) on the physicomechanical properties of 
the matrices and on drug release behavior from the matrices were evaluated. DPH was 
directly combined with PA6,10 in the outer layer. The two subsequent layers were not loaded 
with drug.  
 
Table 3.2 contains the quantities of constituents used in the various formulations prepared 
for comparative analysis of matrix hardness and drug release behavior of the PA6,10 layer. 
The same procedure was carried out for the preparation of tablets for assessment of drug 
release from the s- PLGA layer where the outer layer was composed of various quantities of 
s-PLGA and PEO, Table 3.3 contains the quantities used for these formulations.  
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Figure 3.1: Schematic diagram of the TLT. 
 
Table 3.2: Quantities of constituents used in preparation of TLT formulations – assessment 
of drug release from PA6,10 layer*. 
Experiment PA6,10 (mg) Additives (Salts) 
1 200 - 
2 300 - 
3 350 - 
4 250 50mg sodium sulphate 
5 250 50mg calcium chloride 
6 250 50mg zinc sulphate 
7 250 75mg sodium sulphate 
8 100 250mg sodium sulphate 
9 200 150mg sodium sulphate 
10 300 50mg sodium sulphate 
* All formulations contained 50mg DPH in outer layer. The middle and third layers of every formulation consisted 
of 350mg PEO and 350mg PA6, 10/salted-out PLGA respectively. 
 
Table 3.3: Quantities of constituents used in preparation of TLT formulations – assessment 
of drug release from s-PLGA layer* 
Experiment Salted-out PLGA (mg) PEO (mg) 
1 300 - 
2 250 50 
3 200 100 
4 300 50 
5 50 300 
6 150 200 
7 225 125 
* All formulations contained 50mg DPH in outer layer. The middle and third layers of every formulation consisted 
of 350mg PEO and 350mg PA6, 10/salted-out PLGA respectively. 
 
3.2.2.6. Computational modeling to determine the nature of formation and dissolution 
behavior of the TLT 
 
Computational and molecular modeling was employed to characterize the potential 
interactions that may occur between the polymeric layers of the matrices at a molecular level 
due to compression and to characterize the possible formation, layering and dissolution 
behavior of the TLT matrices. Schematic models depicting the compressed layers and matrix 
formation and drug/matrix bonding were generated on ACD/I-Lab, V5.11 (Add-on) software 
(Advanced Chemistry Development Inc., Toronto, Canado, 2000).  
 
3.2.2.7. In vitro dissolution studies for DPH release analysis  
 
In vitro drug release studies were performed on the different formulations using a USP 25 
rotating paddle method in a dissolution apparatus (Caleva Dissolution Apparatus, model 
Layer 1: PA6,10+salt+drug 
Layer 2: PEO+drug 
Layer 3: s-PLGA+PEO+drug 
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7ST; G.B. Caleva Ltd., Dorset, UK) at 50 rpm with 900mL simulated gastric fluid (SGF) (pH 
1.2, 37°C) and 900mL phosphate-buffer solution (PBS) (pH 6.8; 37°C). A stainless steel 
mesh was used in the dissolution vessels in order to prevent the formulations from floating. 
Samples of 5 mL were drawn at predetermined time intervals over a 24 hour period. 
 
3.2.2.8. Determination of matrix swelling and gel strength using textural analysis 
 
The outer s-PLGA-PEO layer was assessed in terms of axial and radial swelling, under 
conditions identical to those described for in vitro dissolution testing i.e. tablets were 
subjected to analysis in 900mL SGF (pH 1.2, 37°C) and 900 mL PBS (pH 6.8, 37°C) using a 
USP 25 rotating paddle method in a dissolution apparatus (Caleva Dissolution Apparatus, 
model 7ST; G.B. Caleva Ltd., Dorset, UK) at 50 rpm.  The other two layers were coated with 
a 10% EC coating which was 5g in 50mL of acetone to prevent them from swelling/eroding in 
the dissolution medium. 
 
3.2.2.9. Assessment of erosion of the modified PA6,10 layer 
 
The outer PA6,10 layer was assessed for erosion in terms of percentage mass loss under 
the same conditions; the tablets were weighed before testing and dried and re-weighed after 
testing. Equation 3.1 was used to calculate percentage mass loss (%ML).   
 
At each time interval the matrices were removed from the apparatus, measured in terms of 
swelling size, the gel was subjected to textural analysis in order to determine gel strength 
and FTIR analysis in order to determine changes in molecular structure upon hydration and 
swelling.  
            
                                              100)(% ×
Μ
Μ−Μ
=
I
FIML                               
                                                                                                                              Equation 3.1 
 
Where MI is the initial mass of the matrix, and MF is the final mass of the same dried and 
partly eroded matrix. 
 
3.2.2.10. Determination of matrix hardness 
 
Formulations were assessed for matrix hardness using a calibrated TA.XTplus Texture 
Analyzer (Stable Microsystems, UK). The analyzer was fitted with a steel probe (3.125mm 
diameter). The probe was lowered such that the ball made an indentation of predetermined 
distance (0.5mm) on the matrix layer. Force-distance profiles were generated for the various 
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formulations and along with the Brinell hardness equation was used to calculate matrix 
hardness and Brinell hardness numbers (BHN) (N/mm2). Brinell hardness numbers for 
various formulations were obtained using the maximum force of resistance as a variable.  
Specific parameters were set for the assessments which are depicted in Table 3.4 
 
                                                                           
  
 
 
        Equation 3.2 
 
Where P is the load/applied force (kg), D is the steel ball diameter (mm) and d is the 
depression diameter (mm). 
 
Table 3.4: Textural analysis parameters for the assessment of BHN 
Parameter Settings 
Pre-Test speed 1mm/s 
Test speed 
Post-test speed 
Compression force 
0.5mm/s 
1mm/s 
40N 
Trigger type Auto 
Load cell 50kg 
 
3.2.2.11. Molecular mechanics simulations 
 
All modeling procedures and calculations, including energy minimizations in molecular 
mechanics, were performed using the HyperChemTM 8.0.8 Molecular Modeling System 
(Hypercube Inc., Gainesville, Florida, USA) and ChemBio3D Ultra 11.0 (CambridgeSoft 
Corporation, Cambridge, UK). The octamers of s-PLGA and PEO and dimer of PA6,10 were 
generated from standard bond lengths and angles employing polymer builder tools using 
ChemBio3D Ultra in their syndiotactic stereochemistry as 3D models and were saved in .skc 
file format readable to HyperChem 8.0.8.  
 
The models were initially energy-minimized using a MM+ Force Field and the resulting 
structures were again energy-minimized using the Amber 3 (Assisted Model Building and 
Energy Refinements) Force Field. The conformer having the lowest energy was used to 
create the polymer-cation and polymer-polymer complexes. A complex of one polymer 
molecule with another was assembled by disposing the molecules in a parallel way, and the 
same procedure of energy-minimization was repeated to generate the final models: PA6,10-
Na2+, PA6,10-Ca2+,
 
PA6,10-Zn2+ and s-PLGA-PEO.  
 
Full geometry optimization was carried out in vacuum employing the Polak–Ribiere conjugate 
gradient algorithm until an RMS gradient of 0.001kcal/mol was reached. Force field options in 








2
d-
2
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the AMBER (with all hydrogen atoms explicitly included) and MM+ (extended to incorporate 
non-bonded cut-offs and restraints) methods were the HyperChem 8.0.8 defaults. For 
molecular mechanics calculations, the force fields were utilized with a distance-dependent 
dielectric constant scaled by a factor of 1. The 1-4 scale factors were electrostatic 0.5 and 
van der Waals 0.5. 
 
3.3. Results and Discussion 
 
3.3.1. Molecular variations after compression of matrices employing Fourier Transform 
Infrared Spectroscopy  
 
The analysis on compressed and plain PA6,10 showed no significant differences in terms of 
the spectra generated indicating that little/no structural variations occur after compression. 
Figure 3.2a exhibits a typical FTIR spectrum of the comparison between non-compressed 
and compressed PA6,10. The spectra showed very similar prominent peaks indicating no 
significant difference in chemical composition in the different dissolution mediums. The peaks 
show:  NH stretching (at 3300-3305cm-1); trisubstituted CH stretching (at 3072-3077cm-1); 
alkyl CH stretching (at 2852-2922cm-1); strong: pyridyl C-C and C-N stretching (at 1633-
1634cm-1); NH bending (at 1535-1536cm-1); CH2 deformation (at 1465-1467cm-1); CH out-of-
plane deformation (at 679-682cm-1); H – C=O bend in aliphatic aldehydes (at 1418cm-1). A 
peak at 1102 is indicative of C-OH stretching possibly due to H-bonding.  No structural 
interaction was noted between PA 6,10 and sodium sulphate after compression. The same 
was noted for s-PLGA. The spectra showed very similar prominent peaks which include: C-H 
stretching (at 2920-2952cm-1); C=O stretching (at 1745-1750cm-1); C=C stretching (at 1635-
1636cm-1); – CH3 (at 1452,1465 and 1384cm-1); H-C=O bend in aliphatic aldehydes (at 
1341cm-1); C-N stretching (at 1162cm-1); Si-O-C stretching or C-OH stretching (at 1076-
1080cm-1,1084-1095cm-1); C-C stretching (at 948-960cm-1); C-C stretching/C-H bending/C-N 
stretching (at 847-869cm-1); out of plane CH deformation (at 840-841cm-1). 1600-1900cm-1 
(C=O) bands were noted, which confirm the cross-linking bonds between the salt (sodium 
chloride) and oxygen molecules in PLGA, hydrogen bonds, ether bonds (Sibambo et al., 
2008). No molecular interaction was found between PEO and s-PLGA after compression 
(Figure 3.2b). This proved that compression and hydration did not affect the inherent nature 
of the polymers and drug release from the polymer matrices is attributed to the nature and 
characteristics of the polymers. 
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Figure 3.2: a) FTIR Spectrum of compressed and non-compressed PA6, 10, b) FTIR spectra 
of compressed s-PLGA, compressed PEO and combined compressed s- PLGA and PEO. 
 
Analysis on hydrated PA6,10 samples also revealed no significant structural changes upon 
hydration of the matrices. Characteristic bands and peaks remained noticeable. FTIR 
performed on the hydrated swelled s-PLGA-PEO layer showed that no significant structural 
changes occurred with each polymer, there was no merging of peaks or the formation of new 
peaks which indicates no interaction or molecular variations. Broad bands at 3370-3384cm-1 
represent water due to hydration of the formulation. This lack of interaction is visible to the 
eye upon removal of the formulations from the dissolution medium.  
 
 
 
b) 
a) 
Uncompressed  
Compressed  
Compressed  s-PLGA 
Compressed  PEO 
Compressed s-PLGA 
and PEO 
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3.3.2. DSC and ADSC analysis for the determination of thermal variations and 
molecular interactions 
 
DSC was carried out on samples in order to determine changes in thermal behavior after 
compression as well as after combination with other materials. The thermograms obtained 
from the polymers are shown in Figure 3.3. Plain PA6,10 exhibited a thermal transition at 
~50°C, which relates to its glass transition temperature which suggests that it is crystalline at 
room temperature (25°C). Another transition occurred between 200-220°C which might be 
rationalized as the melting point. This was confirmed by the investigations of Kohan (1999). 
The thermogram displayed by the compressed PA6,10 displayed the same thermal 
transitions occurring as the pure polymer indicating that there is minimal or no variation to 
PA6,10 after compression. Compressed PA6,10 also remained crystalline.  
 
 
Figure 3.3: DSC thermograms of a) uncompressed PA6,10, b) compressed PA6,10; c) 
uncompressed s-PLGA and d) compressed s-PLGA. 
 
These results establish that no thermal interactions occur which may affect the release of 
drug from the matrices which further confirms the FTIR characterization of the polymer. The 
presence of interactions may have untowardly affected the release of drug from the matrices. 
The compressed combination of PA6,10 and sodium sulphate showed no significant changes 
in the thermal behavior of PA6,10 indicating that no chemical interaction occurred between 
them.  
Melting point 
Melting point overlapping 
with glass transition 
temperature 
Glass transition 
temperature 
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Figure 3.4: DSC and ADSC thermograms of compressed salted-out PLGA and PEO at a) 0-
360°C, b) 0-130°C c) 240-280°C, and d) 40-100°C. 
 
Native s-PLGA exhibited a thermal transition between 50-60°C indicating its Tg. A broad Tm 
peak was observed at 320-340°C. Native PEO showed a thermal transition between 70-80°C 
which is attributed to its melting temperature. The compressed combination of s-PLGA and 
PEO revealed separate Tg and Tm peaks which can be explained by a lack of interaction 
between the two polymers. Alternating differential scanning calorimetry (ADSC) was 
employed to provide a more accurate and comprehensive confirmation of the results. While 
DSC may overlook minute variations, ADSC analysis is a more sensitive analysis of the 
variations that may occur with temperature fluctuations. Thermograms from ADSC analysis 
are provided in Figure 3.4b and c.  
 
3.3.3. Computational modelling of the formation and dissolution of the Triple-Layered 
Tablet 
  
The compressibility of a polymer may have an effect on the interaction of drug in the polymer 
matrix i.e. a higher compressibility will hold the drug; a chemical interaction may occur which 
may be ionic or covalent leading to changes in structure of the drug or an inter-play may 
occur between the drug and matrix where the drug is in a free floating embedded state but is 
tightly surrounded by the polymer matrix. This occurrence may be likened to submerged or 
Glass transition temperature 
of s-PLGA 
Melting point of PEO 
a) b) 
c) d) 
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embedded balls in ice cubes where there is no interaction between the ball and ice matrix. 
The additional energy that is supplied due to compression energy is absorbed onto the drug 
molecules as well as the polymer matrix may partake in stabilization of the free floating 
system. The energy will be released making dissolution faster on contact with the dissolution 
medium. The TLT as depicted in Figure 3.5a displays layers of polymers loaded with drug 
molecules (circular entities). Intermixed or combined layers that are depicted may occur with 
occasional drug entrapments due to heavy compressions applied for the different polymer 
layers. Figure 3.5b demonstrates the actual formation of the layers. The first polymer with 
drug loaded is compressed followed by the second drug-loaded polymer and finally the third 
polymer and drug layering sequentially on one another. The intermixed polymer layers are 
also shown which are expected to intermingle due to adhesion. Drug molecules may also 
seep into other polymer layers due to high compression forces. 
 
 
Figure 3.5: a) Compressed TLT containing layers of polymer matrices and drug with 
intermixed layers; b) different layering in the compressed tablet formation; c) disintegration of 
the compressed TLT in the dissolution medium. 
 
A predictable approach to the dissolution of the TLT was adopted. There is a high possibility 
of the polymer becoming solvated because the compressed polymer will not immediately 
Polymeric layer 1 
Polymeric layer 2 
Polymeric layer 3 
Addition of first 
polymeric layer 
Addition of second and third 
polymeric layer subsequent 
to precompression of first 
and second polymeric layer 
Precompression of 
first polymeric layer 
Intermixed layer 1 
Intermixed layer 2 
Intermixed layer  
Round shaping of 
the matrix 
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dissolve out. However, the dissolution medium may interact with the portions of the 
compressed polymer strands and the polymer may swell in the case of it being hydrophilic. In 
the case of the polymer not being hydrophilic, the dissolution medium may then relax the 
compression of the matrix. The relaxation occurs akin to the slow melting of the ice cube 
embedded ball model to release the drug from the embedded matrix.  
 
The rate of solvation of the matrix is higher than the rate of disintegration that would be the 
slowest to occur. There is initially a slow dissolution of the polymer layer in the dissolution 
medium with extremely slow dissolution occurring at the outer curve of the layers and the 
intermixed layers. The inner areas of the layer are more prone to dissolution resulting in a 
round shaping of the matrix as depicted in Figure 3.5c. The arrows indicate the areas that 
are disintegrating in the dissolution medium. This is where the matrix loses a major part of 
the polymer matrix and solvated, polymer embedded or chemically conjugated drug. It is 
predicted that the less compressible polymer will disintegrate more rapidly thereby releasing 
drug faster. The multidirectional dissolution that occurs, leaving the outer edges and 
intermixed layers most intact, balances out the release and the cumulative drug release 
appears to be linear or near linear.  
 
3.3.4. In vitro drug release from the TLT formulations 
 
3.3.4.1 Assessment of DPH release from the PA6,10 layer 
 
Figure 3.6a and b display the calibration curves constructed for DPH. It was discovered that 
using a quantity of 300mg PA6,10 depicted the most desirable, near linear release profile 
that could be explained by a more compact matrix, due to the higher packing density making 
the matrix more resistant to penetration by the dissolution medium, resulting in more 
adequate retardation of drug release as depicted in Figure 3.7a, than with a smaller quantity 
of PA6,10. However there was an occurrence of an undesirable initial burst release of drug. 
The addition of various salts to the layer was investigated in an attempt to eliminate the initial 
burst release. The formulations containing SS (as an additional salt to PA6,10 layer) 
demonstrated the highest capability in reducing the burst release and exhibited a linear 
release profile with no burst release as shown in Figure 3.7b. Various ratios of PA6,10 to SS 
were prepared and the most linear release over 24 hours was achieved with 300mg: 50mg 
(Figure 3.7b).  
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Figure 3.6: Calibration curve for the determination of DPH in a) SGF (pH 1.2, 37°C) and b) 
PBS (pH 6.8, 37°C). 
 
   
Figure 3.7: DPH release profiles from a) 300mg PA6,10 layer; b) 300mg PA6,10 and 50mg 
SS (N=2). 
 
3.3.4.3. DPH release from the s-PLGA layer 
 
Direct combination of s-PLGA with DPH exhibited a significant burst release of 6% and total 
drug release within 4 hours in SGF (pH 1.2, 37°C) with a 28% burst release in PBS (pH 6.8, 
37°C) (Figure 3.8a) and total drug release before 24 hours. This may be due to the possibility 
that s-PLGA utilized unaccompanied as a matrix may not be adequate to retard drug release 
due to the inability to form a sufficiently compact matrix that may be explained by the 
crystalline nature of the polymer. Another contributing factor is that s-PLGA is hydrophobic 
(Sibambo et al., 2007) and therefore does not swell. The formulations containing the addition 
of PEO to the s-PLGA layer showed more desirable results in terms of a reduced burst 
release and a more linear release profile. The proposed rationale for the addition of PEO is 
that it increases the elasticity of the layer which allows for a more constant diffusion path 
length and a more constant release of drug over time. From the various ratios of s-PLGA to 
PEO the results showed that the 50mg: 300mg ratio showed the most desirable release 
profile in SGF (pH 1.2, 37°C)  and PBS (pH 6.8, 37°C) as can be seen in Figure 3.8b. 
 
a) b) 
a) b) 
y=1.106x 
R2= 0.999 
y=1.199x 
R2= 0.995 
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3.3.4.4. Drug release from the middle PEO layer 
 
The release profile of DPH from the middle PEO layer proved to be near linear (as displayed 
in Figure 3.9) this may be due to the uniform swelling of the polymer as only two of the 
surfaces are exposed to the dissolution medium. The release extended over 24 hours in SGF 
(pH 1.2, 37°C) and only approximately 30% was released after 24 hours in PBS (pH 6.8, 
37°C). A constant quantity of 350mg of PEO was selected as a drug matrix. 
 
 
Figure 3.8: Drug release profiles from a) 300mg s-PLGA; b) 50mg s-PLGA: 300mg PEO 
(N=2). 
 
Figure 3.9: DPH release profiles from 350mg PEO (N=2). 
 
3.3.5. Determination of axial and radial swelling and gel strength upon hydration of the 
TLT formulations 
 
The two formulations that were analysed showed small increases in diameter and thickness 
of the swollen layer over 24 hours. The changes in diameter and thickness are noted in 
Table 3.5. The matrices were found to swell to a slightly greater extent in PBS (pH 6.8, 37°C) 
as compared to SGF (pH 1.2, 37°C). Figures 3.10a, b and c display force-distance profiles of 
the 150:200 s-PLGA-PEO layer after 2, 12 and 24 hours of hydration in SGF (pH 1.2, 37°C). 
It has been observed that the force of resistance that the probe experiences as it penetrates 
the swollen layer is dependent on the distance that the probe travels into the gel layer (Yang 
et al., 1998). 
a) b) 
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The profiles obtained show that there is an initial low resistance to penetration at the surface 
of the layer and an increased resistance to penetration deeper into the layer indicating an 
increase in the gel strength advancing into the swollen layer. The results also indicate that at 
a higher degree of hydration, the gel strength decreases with a lower resistance to 
penetration by the probe. The formulations did not show a great increase in swelling 
especially between 12 and 24 hours therefore in some cases the force of resistance to 
penetration did not increase after 24 hours of hydration. Evidently, the formulation with a 
higher amount of PEO showed a greater extent of swelling and a higher force of resistance 
indicating greater gel strength of that layer. 
 
 
Figure 3.10: a) Force-distance profile for the s-PLGA layer after 2 hours of hydration in SGF 
(pH 1.2, 37°C), b) Force-distance profile generated for s-PLGA layer after 12 hours of 
hydration in SGF (pH 1.2, 37°C) and c) Force-distance profile generated for s-PLGA layer 
after 24 hours of hydration in SGF (pH 1.2, 37°C). 
 
Table 3.5: Changes in thickness and diameter of the gel layer after 2, 12 and 24 hours of 
hydration of the s-PLGA-PEO formulations 
 Ratio 
(mg) 
Dissolution 
Medium 
 Diameter 
(mm) 
  Thickness 
(mm) 
 
  
2hrs 12 hrs 24 hrs 2hrs 12 hrs 24hrs 
50   : 300 SGF 16 20 23 5 6 7 
150 : 200 SGF 13 18 20 4 5 5.5 
50   : 300 PBS  14 22 25 5 7 8 
150 : 300 PBS 13 20 21 4 6 7 
 
b) a) 
c) 
Maximum 
Force used 
for gel 
strength 
analysis 
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3.3.6. Determination of degree of erosion of the PA 6, 10 layer upon hydration over 24 
hours in correlation with drug release behavior 
 
Polymer erosion can be defined as the process by which a polymer hydrolyzes and 
disappears into its environment (Yu et al., 2008). Nylon is an erodible polymer (Kydonieus, 
1999), which can be observed from the results. Results from erosion studies performed on 
formulations containing 300mg PA6,10 and 300mg PA6,10:50mg sodium sulphate 
demonstrated an approximate 3% mass loss of the matrices over 24 hours. Table 3.6 
displays the changes in weight and percentage mass loss of the formulations after 2, 12 and 
24 hours. As the time of exposure to the dissolution medium increased, percentage mass 
loss also increased for all formulations.  
 
The formulation with sodium sulphate showed a greater percentage mass loss which is due 
to the quicker dissolution of sodium sulphate in the dissolution medium. It is logical that an 
increase in erosion of PA6,10 will allow for greater drug surface exposure to the dissolution 
medium (Danckwerts, 1994), however the rate at which this occurs contributes towards 
controlling drug release i.e. a slower rate of erosion allows for slower drug release. Thus the 
maintenance of a constant surface area for drug diffusion during dissolution is critical for 
zero-order drug delivery (Sundy et al., 2004; Liu et al., 2008). 
 
Table 3.6: Percentage mass loss of PA 6,10 formulations after 2, 12 and 24 hours of 
hydration. 
Formulation Dissolution 
medium 
Percentage Mass Loss (%) 
  2hours, mean  
± S.D. 
12 hours, mean  
± S.D. 
24 hours, mean  
± S.D. 
300mg PA6,10 SGF 1.00% ± 0.14 0.70% ± 0.10 17.4% ± 2.42 
300:50mg SS SGF 1.32% ± 0.56 2.35% ± 0.84 40.4% ± 1.98 
300mg PA6,10 PBS 0.79% ± 0.14 1.25% ± 0.14 19.4% ± 0.14 
300:50mg SS PBS 1.17% ± 0.35 1.88% ± 0.00 1.95% ± 0.00 
 
3.3.7. Effect of matrix hardness on drug release behavior 
 
Table 3.7 exhibits the BHN values for various TLT formulations. The BHN analysis revealed 
that the formulations comprising higher quantities of PA6,10 and s-PLGA possessed higher 
BHN values which may be attributed to the formation of a more compact matrix at higher 
polymer quantities. It has been proven that matrix hardness can noticeably influence drug 
release behavior (Apu et al., 2009). This can be correlated to the drug release from these 
matrices, DPH release from the formulations containing higher quantities of PA6,10 were the 
most sustained and linear over 24 hours. This is explained by a more compact, hard matrix 
that is able to retard drug release more efficiently. The addition of SS may also have a role to 
play in the compactness of the matrices due to the crystalline nature that it possesses. 
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Table 3.7: BHN for PA 6,10 formulations. 
Formulation BHN (N/mm2) ± S.D. 
300mg PA6,10:50mg SS 17.31 ± 1.13 
200mg PA6,10: 150mg SS 13.74 ± 0.17 
50mg s-PLGA:300mg PEO 11.98 ± 0.47 
150mg s-PLGA: 200mg PEO 14.32 ± 0.64 
 
The formulations containing higher quantities of s-PLGA however, did not provide desirable 
release of DPH. The higher quantity of PEO was found to be necessary for the uniform 
release of DPH. Figure 3.11 shows a typical force-distance profile generated from the 
Texture Exponent 32 software (StableMicroSystems, Surrey, UK). 
 
In general, the TLT formulations do not have high BHN values that could be explained by the 
low compression force of 3 tons that they are subjected to, although the effect that 
compression force had on hardness was found to be modest.  
 
 
Figure 3.11: Typical force-distance profile for 50mg s-PLGA: 300mg PEO. 
 
3.3.8. Molecular mechanics assisted model building and energy refinements, influence 
of addition of salts on the performance of PA6,10 layer 
 
The polyamides display a wide range of physicomechanical properties when complexed 
physically, chemically or physicochemically with metal cation in form of metal salts which 
mainly rest on their ability to form Lewis acid-base complexes (Mit-uppatham et al., 2004; 
Gupta et al., 2009). A generalized molecular mechanics program was used in this study to 
compute the energy attributes of PA6,10 and PA6,10-cation conformations. PA6,10 
interactions were screened for the three metal cations (Na+, Ca2+ and Zn2+) in an attempt to 
corroborate and elucidate the experimentally observed drug release profiles. The cation 
probe was moved around the van der Waals surface of the amide chain and the energy 
minimized structures following molecular mechanics simulations are depicted in Figure 3.12 
Force (N) 
Distance (mm) 
Max. Force  
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and the possible component binding energies, and the intrinsic molecular attributes to which 
they will be responsive, are listed in Table 3.8. The polyamide chain assumed a 
intramolecular, tail-head, bonded, ordered structure (Figure 3.12a and b) after geometry 
optimization. The cation binding was evident from the presence of binding sites distributed in 
ordered arrays and formed between chains (Figure 3.12c, d and e). It is evident from the 
energy attributes that PA6,10-Na+ (∆E=-92.02kcal/mol) and PA6,10-Ca2+
 
(∆E=-62.72kal/mol) 
were forming more thermodynamically stable conformers than that of Zn2+ (∆E=-2.29kal/mol). 
These energy minimizations were supported both by bonding interactions (angle energy) and 
non-bonding interactions (van Der Waals forces). These two energies seem to be 
complementary to each other in this case. The bond angle contributions, reference values 
assigned to all of the bond angles for the structure may arise from the force between two 
instantaneously induced dipoles (London dispersion force) and the resulting steric 
adjustment caused due to inclusion of metal ions in the polymer matrix.  
 
 
Figure 3.12: Geometrically constrained models of the polyamide-metal ion complexes 
derived from molecular mechanics calculations: (a) PA6,10-non energy-minimized; (b) 
PA6,10-energy minimized; (c) PA6,10-Ca2+; (d) PA6,10-Zn2+; and (e) PA6,10-Na+. Color 
codes for elements are: Carbon (cyan), Nitrogen (blue) and Oxygen (red), Calcium (yellow), 
Zinc (brown) and Sodium (purple). 
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The significant lowering of angle energy [PA6,10-Na+ (∆E~-52kcal/mol) and PA6,10-Ca2+
 
(∆E~-50kal/mol)] and vdW energy [PA6,10-Na+ (∆E~-40kcal/mol) and PA6,10-Ca2+
 
(∆E~-
13kal/mol)] demonstrate the efficient fitting of metal ions with aliphatic groups of the polymer 
chain. The complexation of these metal ions with polyamide chain may be governed by the 
values of the surface coordination number, ionization potential and ionic radius of the metal 
cations as described by (Frolov et al., 1999). The metal ion with largest ionic radius may form 
a close packed geometry conformation maximally filling the available lattice space (Figure 
3.13e). The results obtained demonstrated the importance of the structural features of the 
oligosaccharide chains and the steric arrangement of the active groups where the cation-
interaction displays considerable stereospecificity, proper spacing and geometry of the 
coordination shell. 
 
Table 3.8: Calculated energy parameters for the molecular assemblies involving PA6,10,  
s-PLGA and PEO. 
Structure Energy (kcal/mol) 
Total ∆Ebinding Bond Angle Dihedral VDW ∆Evdw H bond 
PA6,10 64.425 -- 1.153 54.931 4.771 3.963 -- -0.391 
PA6,10-Zn2+ 62.135 -2.29 1.076 52.586 8.739 -0.267 -4.23 -0.0003 
PA6,10-Ca2+ 1.709 -62.72 0.619 4.256 6.361 -9.434 -13.397 -0.093 
PA6,10-Na+ -27.595 -92.02 0.266 2.400 5.439 -35.701 -39.664 0 
s-PLGA 2.638 -- 0.288 2.534 0.885 -1.062 -- -0.007 
PEO 12.635 -- 0.216 0.985 7.003 4.431 -- -0.001 
s-PLGA-PEO 2.571 -25.343 0.639 4.612 18.112 -19.896 -27.696 -0.902 
∆Ebinding = E(Host.Guest) - E(Host) - E(Guest) 
∆Evdw = Vdw(HostGuest) - VdW(Host) - VdW(Guest) 
 
This complexation between surface electron-donor groups of the PA6,10 fibre and metal 
cations may be responsible for the altered physicomechanical (breaking load) and 
physicochemical properties of the fibre (by decreasing or increasing the effective pore size). 
It may be too difficult for the drug to be entrapped into the polyamide matrix because of very 
high intermolecular bonding between the polymer filaments as shown in Figure 3.13. In this 
way, drug may remain outside the matrix and be released as soon as it comes in contact with 
dissolution media (high initial burst release). However, addition of metal salts (monovalent or 
divalent) may cause breaking of these intermolecular bonds, thereby creating space for the 
drug molecules to be embedded into the polymer matrix (Gupta et al., 2009) (Figure 3.13). 
Additionally, water being a stronger Lewis base than nylon may cause leaching of salt 
molecules creating a porous matrix architecture.  
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Figure 3.13: Schematic of reference polyamide with a) intermolecular hydrogen bonds and 
b) polyamide complexed with ZnSO4 . 
 
Sodium ions, having larger binding energy and more stabilized complex, may delay the 
release culminating in the release of drug to a lesser extent (lowered initial burst release). 
This is also evident from the geometrical preferences shown in the polymer salt complexes, 
(Figures 3.12c, d and e), where sodium ions are forming a dense matrix structure than 
calcium and zinc. Additionally, Mit-uppatham and co-workers  described that the viscosity 
value of polyamide solutions increases with the addition of monovalent ions such as Na+ and 
Li+ (as compared to divalent ions such as Mg2+) due to an increase in the viscoelastic force 
(Mit-uppatham et al., 2004). This increase in viscosity may be a determining factor for the 
zero-order controlled release profile due to inclusion of Na2SO4. These results in conjunction 
with the comparable FTIR spectra of the non-compressed and compressed matrices 
indicates that the introduction and removal of salts is a reversible process and does not alter 
the final properties of PA6,10. 
 
a) 
b) 
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3.3.9. Influence of the incorporation of PEO on the performance of the s-PLGA layer 
 
The energy minimized structures of the s-PLGA-PEO, before and after molecular mechanics 
simulations, are depicted in Figure 3.14 and the corresponding connolly molecular surface 
structures are demonstrated in Figure 3.15. The possible component binding energies and 
the intrinsic molecular attributes to which they will be responsive, are listed in Table 3.8.   
 
 
Figure 3.14: Visualization of optimized geometrical preferences showcasing the s-PLGA-
PEO complex systems: (a) before and (b) after molecular mechanics’ energy refinements. 
Color codes: s-PLGA (yellow) and PEO (standard element colors: Carbon (cyan), Nitrogen 
(blue) and Oxygen (red). 
 
Invariant factors common to mathematical description of binding energy and substituent 
characteristics have been ignored. It is evident from the energy values that the s-PLGA-PEO 
complex is stabilized by a binding energy ∆E≈-25kcal/mol. The global energy minimum was 
supported mainly by the van der Waals interactions between the polymer molecules (∆Evdw=-
27.696) due to the presence of aliphatic groups in the polymers. These underlying weak 
chemical interactions may not cause a structural change in the polymers but may initiate 
aggregation of the aliphatic chains, as both the polymers synthesized are long chain aliphatic 
polymers, resulting in localized regions with a density and refractive index different from that 
of the bulk polymers. Figures 3.15a and b visualize the comparative molecular surface 
preferences of the two polymers before and after the computational refinement. Additionally, 
the PEO induced intramolecular hydrogen bonding in s-PLGA (≈100 times more than the 
individual polymers) (Figure 3.14b) may influence the hydration process of the PLGA 
polymer matrix. The stratified zero-order drug release along with reduced burst release from 
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the s-PLGA-PEO blend layer of TLT formulations is in line with the earlier reported results 
involving s-PLGA–PEO polymeric blend films and microparticles by Santander-Ortega et al. 
(2010).  
 
Figure 3.15: Connolly molecular electrostatic potential surfaces in translucent display mode 
showcasing the PLGA-PEO complex systems: (a) before and (b) after molecular mechanics’ 
energy refinements. Color codes: PLGA (yellow) and PEO (red). 
 
3.4. Concluding Remarks 
 
It was elucidated that the employed novel polymers have shown significant potential as outer 
layer drug matrices in the TLT formulations for potential zero-order drug release. Linear 
profiles were observed from all three layers of specific formulations. It was determined that 
each layer should have a weight of 400mg including 50mg of drug for optimum results. The 
ratio of polymers to salt and other polymers were proven to have an effect on the 
physicomechanical properties of the matrices and had an influence on drug release behavior. 
It is logical that the intimate selection of appropriate polymer and excipient ratios are critical 
in achieving the desired drug release outcomes. The Molecular Mechanics simulations 
demonstrated that the obtained release pattern may be attributed to the modified matrix 
hydration process of PLGA (hydrogen bonding induced by the presence of the PEO) and 
continued retarded release of the PEO derivative due to its entanglement with the polyester 
chains as was shown in connolly molecular surface architecture. The matrices exhibited 
much promise for the controlled delivery of various drugs including those with high water-
solubility. Further research will focus on the optimization of the TLT formulations. It is 
apparent that the proposed system potentially offers a significant positive impact on patient 
compliance and therefore therapeutic efficacy. 
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CHAPTER 4  
EXPERIMENTAL DESIGN AND STATISTICAL OPTIMIZATION OF THE TRIPLE-
LAYERED TABLET MATRICES 
 
4.1. Introduction 
 
The preformulation studies summarized in the previous chapter were essential for identifying 
formulation factors (independent variables) used in the optimization of the triple-layered 
tablet (TLT) matrices. The independent variables previously mentioned are outlined in this 
chapter. It is known that in modern years, chemometric approaches are commonly applied to 
the optimization of scientific systems (Ferreira et al., 2007). This approach carries various 
advantages such as condensing the amount of experiments and therefore laboratory work 
that is required and subsequently a reduction in the amount of chemicals that are used.  
 
Multivariate design of experiments allow for the determination of important interactions 
between the different experimental variables that may occur permitting a more accurate 
optimization of the systems. An experimental design was employed in the study whereby the 
aforementioned variables were varied accordingly in order to evaluate measured responses 
of the TLT formulations.  
 
Response surface methodology was opted for while the experimental design was being 
executed. This was selected in order to determine the optimal combination of the formulation 
constituents. This methodology along with a Box-Behnken design was employed to optimize 
the TLT. Hence, the process of optimization that was utilized involved a number of steps that 
were conducted in a specific manner which includes developing a design of experiments 
utilizing the formulation independent variables, conducting in vitro tests on the formulations 
generated in the design of experiments, employing regression analysis to determine the 
coefficients of a mathematical model and the forecasting of the dependent variables or 
measured responses.  
 
Two new model drugs were introduced to the TLT in order to generate more in depth in vitro 
drug release results for ultimate optimization of the TLT. Hence, the aim of this chapter was 
to outline the comprehensive in vitro analysis of the Box-Behnken design formulations with 
specific focus on the two valid experimental responses that were selected. The results 
obtained were aided by specific contour plots and diagnostic plots to assess the relationships 
between constituents that may have been established and to assess the efficiency of the 
Box-Behnken design. 
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4.2. Materials and Methods 
 
4.2.1. Materials 
 
Ranitidine hydrochloride (RDH), promethazine (PMZ) and chlorpromazine (CP) were 
purchased from Sigma Chemical Company (St Louis, MO, USA). HPLC grade Acetonitrile 
(ACN) was purchased from Microsep (Johannesburg, South Africa). Potassium dihydrogen 
phosphate and methyl paraben (MP) was purchased from Rochelle Chemicals 
(Johannesburg, South Africa). All other reagents used are of analytical grade. 
 
4.2.2. Methods 
 
4.2.2.1. Determination of appropriate independent formulation variables to explicate 
desired responses for the TLT matrices 
 
Separate factors were chosen for each constituent of the TLT matrices in order to be capable 
of generating specific mathematical models per constituent. The most fundamental variables 
to be considered were the quantities of PA6,10 and SS in the first layer and s-PLGA and 
PEO in the third layer. Thus the independent variables were quantitative in nature.  
 
Patterns were observed with regards to the amount of PA6,10 utilized in the formulation and 
the effect of this on drug release behavior from the preformulation studies.  These patterns 
were quantified and used as upper and lower limit variables for drug release. Further 
patterns were noted with the amount of s-PLGA and PEO utilized in the third layer. Thus the 
quantities of each individual polymer were allocated upper and lower limits and used as 
variables for the optimization of the TLT matrices. For the purposes of this study the 
responses selected for optimization were rate constants (k) and correlation coefficients (R2 
values).  Rate constants were to be obtained corresponding to those of zero-order drug 
release kinetics while correlation coefficients were to be maximized in order to obtain an 
optimal formulation. Table 4.1 displays the formulation variables and responses with the goal 
of TLT optimization. These values were selected according to the desired drug release 
profiles from the TLT matrices. The drug release profiles from all the layers would be 
required to be linear or near linear (zero-order) for the desired outcome of this study. 
 
Each of the three drugs incorporated into the formulations would need to be released at a 
constant rate per a predetermined time interval over 24 hours. This was to be attempted in 
the anticipation that as drug is released it is being absorbed in the same ratio and quantity 
that it was released. During the preliminary studies, the formulations that essentially 
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displayed similar release profiles to the desired release profiles were selected for further 
studies and variable development. 
 
Table 4.1: Formulation variables and responses for TLT optimization. 
Independent variables Upper limits Lower limits 
PA6,10 (mg) 300 100 
SS (mg) 150 50 
s-PLGA (mg) 300 50 
PEO (mg) 300 50 
Response Upper limits Lower limits 
Rate constant (k) 
Correlation coefficient (R2) 
0.06 
1 
 
0.039 
0.7 
 
It was noted that the quantity of PA6,10 added to the formulation had a significant impact on 
the retardation of drug release from the TLT matrices. It was elucidated that a more 
substantial quantity of PA6,10 was required for adequate retardation and control of drug 
release from the first layer. The same was noted for the ratio of s-PLGA to PEO in the third 
layer. A lower ratio displayed a more desired control of drug release from the third layer. 
Thus specific numerical values for the independent variables were selected according to 
influence they had on the drug release profiles. 
 
4.2.2.2. Box-Behnken Experimental Design for the evaluation of drug release from the 
TLT matrices 
 
A Box-Behnken Experimental Design was generated with experimental runs, essentially, 
being the basic backbone of the design. The rationale behind this was fundamentally to 
minimize the quantity of experimental runs that would be necessary to collect the optimal 
amount of data required for adequate interpretation (Karnachi and Khan, 1996; Chopra et al., 
2007). This was also due to the complex nature of data that would be generated from the 
TLT formulations. The design software employed (Minitab® V15, Minitab®, PA, USA) was 
used to generate seventeen (17) formulations that would undergo experimental runs. The 
variable factors for the experimental runs of the TLT matrices are displayed in Table 4.2. The 
experimental (measured) responses that result from the design of experiment stage are 
utilized to establish an adequate mathematical model that may explain the relationship of the 
variables with the measured outcomes (responses). 
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Table 4.2: The Box-Behnken design experimental runs employed to optimize TLT 
formulations displaying the possible combinations of polymers and excipients that were 
utilized.  
Experiment Layer 1 (outer) Layer 2 (middle) Layer 3 (outer) 
 s- PLGA (mg) PEO (mg) PEO (mg)   PA 6,10 (mg) SS (mg) 
1 300 50 350 300 50 
2 50 300 350 200 150 
3 238 113 350 275 75 
4 175 175 350 250 100 
5 207 142 350 263 87 
6 131 219 350 241 109 
7 50 300 350 300 50 
8 117 233 350 280 70 
9 113 238 350 275 75 
10 219 131 350 241 109 
11 300 50 350 200 150 
12 238 113 350 225 125 
13 142 208 350 263 87 
14 113 238 350 225 125 
15 70 280 350 233 117 
16 233 117 350 280 70 
17 280 70 350 233 117 
 
4.2.2.3. Selection of measured formulation responses for the experimental 
optimization of TLT formulations 
 
The selected measured responses employed for optimization of the TLT formulations were 
rate constants (k values) and correlation coefficients (R2 values). The Peppas model 
(Equation 4.1.) was utilized to generate rate constants by fitting in the individual values per 
design formulation. In vitro drug release data from each of the design formulations were fitted 
to the Peppas model (Equation 4.1). It is known that if the value of the exponent (n) is one, 
zero-order drug release kinetics is followed. It is due to this that the value of n was fixed at 1 
and the ideal rate constant value was obtained. The rate constants for each of the design 
formulations were calculated in the same manner. 
 
nkt
M
Mt
=
∞
        
                                                                                                                              Equation 4.1 
 
Where, Mt is the quantity of drug released at time t; M∞ is the drug loading; k is an 
experimentally determined kinetic constant and n is an exponent that depends on the 
geometry of system and indicates the release mechanism (Davidson III and Peppas, 1986; 
Colombo, 1993). 
 
The k and R2 values were computed for each layer of the TLT formulations i.e. three k and R2 
values were calculated per formulation. Table 4.5 lists the k values for each of the design 
formulations. 
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4.2.2.4. Preparation of the design formulations 
 
Due to the fact that each layer of the TLT would have to be analyzed separately per design 
formulation, a decision was made to incorporate three drugs simultaneously to increase the 
efficiency of the study. Upon investigation it was found that ranitidine HCl (RDH) and 
promethazine (PMZ) possessed the same aqueous solubility as DPH (100mg/mL). This 
proved to be beneficial in further proving the controlled release of highly aqueous soluble 
drug actives. Therefore it was decided that a logical simultaneous incorporation of the two 
drugs into the TLT was favorable. PMZ was incorporated into the middle PEO layer and RDH 
was incorporated into the outer s-PLGA layer. The formulations were prepared by direct 
compression as described in Chapter 3, Section 3.2.2.5. 
 
4.2.2.5. In vitro dissolution testing on the Box-Behnken Experimental Design 
formulations 
 
In vitro drug release studies were performed on the different formulations using a USP 25 
rotating paddle method in a dissolution apparatus (Caleva Dissolution Apparatus, model 
7ST; G.B. Caleva Ltd., Dorset, UK) at 50 rpm with 900mL simulated gastric fluid (SGF) (pH 
1.2, 37°C) and 900mL phosphate-buffer solution (PBS) (pH 6.8; 37°C). A stainless steel 
mesh was used in the dissolution vessels in order to prevent the formulations from floating. 
Samples of 5 mL were drawn at pre-determined time intervals over a 24 hour period. 
 
4.2.2.6. High Performance Liquid Chromatographic analysis of in vitro dissolution 
samples 
 
Analysis of dissolution samples were carried out on a Waters High Performance Liquid 
Chromatography (HPLC) machine (Waters Acquity, Microsep, JHB, South Africa). Adequate 
HPLC method conditions were determined and utilized to analyze dissolution samples from 
the Box-Behnken design formulations. Various methods were attempted in order to obtain a 
chromatographic separation method for the simultaneous determination of all three drugs. 
This was necessary as DPH, PMZ and RDH were loaded into the TLT formulations 
simultaneously in order to perform dissolution testing. Phosphate buffer solution (PBS) (pH 3, 
30°C) and Acetonitrile (ACN) were selected as the mobile phases for the separation method. 
A substantial amount of time was utilized in attempting to develop a suitable method. Finally, 
an isocratic method (as shown in Table 4.3) for the chromatographic quantification of DPH 
was obtained as the determination of all three was not easily achievable. Methylparaben 
(MP) was employed as the internal standard (IS) for calibration and analysis. Figure 4.1 is a 
chromatogram displaying the separation peaks of DPH and MP. Once the chromatographic 
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method was optimized, calibration curves were prepared by running the standards through 
the HPLC column. 
 
Table 4.3: HPLC conditions for the chromatographic analysis of DPH. 
Parameter Condition 
Column Xterra™ RP18, 5µm, 4.6×150mm 
Mobile phase Acetonitrile/20mM potassium dihydrogen 
phosphate pH=3, 35:65 
Flow rate 1mL/min 
Injection volume 20µl 
Detection UV 210nm 
Column Temperature 30°C 
 
The AUC of DPH and MP were noted for each concentration.  The ratio between the AUC of 
DPH and MP was plotted against concentration. Figure 4.2a and Figure 4.2b display the 
calibration curves for DPH quantification in PBS (pH 6.8, 37°C) and SGF (pH 1.2, 37°C)   
respectively.  
 
 
Figure 4.1: Chromatogram depicting the separation peaks of DPH and MP. 
  
Standard stock solutions ranging between 0-0.1mg/mL of DPH, PMZ and RDH were 
prepared both in PBS (pH 6.8, 37°C) and SGF (pH 1.2, 37°C) for the calibration analysis. 
The ratio between the area under the curve (AUC) of the three drugs and the IS was plotted 
against concentration to produce each calibration curve.      
 
   
Figure 4.2: Calibration curves for DPH quantification in a) PBS (pH 6.8, 37°C) and b) SGF 
(pH 1.2, 37°C). 
a) b) 
y=114.2x 
R2= 0.995 
 
y=158.3x 
R2= 0.993 
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Table 4.4 displays the method conditions for the simultaneous determination of PMZ and 
RDH. 
 
Table 4.4: HPLC conditions for the chromatographic analysis of PMZ and RDH. 
Parameter Condition 
Column Xterra™ RP18, 5µm, 4.6×150mm 
Mobile phase Acetonitrile/20mM potassium dihydrogen 
phosphate pH=5, gradient method 
Flow rate 1mL/min 
Injection volume 20µl 
Detection UV 254nm 
Column Temperature 30°C 
 
The mobile phases employed were PBS (pH 5) and ACN using a gradient method as shown 
in Table 4.4. Chlorpromazine (CP) was employed as the IS for calibration and analysis. 
Figure 4.3 is a chromatogram displaying the separation peaks of PMZ, RDH and CP. After 
method optimization, calibration curves were prepared. Figures 4.4a and b depict the 
calibration curves computed for PMZ in PBS (pH 6.8, 37°C) and SGF (pH 1.2, 37°C)  
respectively. Similarly, Figures 4.5a and b depict the calibration curves computed for RDH in 
PBS and SGF (pH 1.2, 37°C). 
 
Figure 4.3: Chromatogram depicting the separation peaks of RDH, PMZ and CP. 
 
  
Figure 4.4: Calibration curves for PMZ quantification in a) PBS (pH 6.8, 37°C) and b) SGF 
(pH 1.2, 37°C). 
b) a) 
 
y=139.97x 
R2= 0.993 
 
y=127.72x 
R2= 0.970 
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Figure 4.5: Calibration curves for RDH quantification in a) PBS (pH 6.8, 37°C) and b) SGF 
(pH 1.2, 37°C). 
 
4.3. Results and Discussion 
 
4.3.1. In vitro drug release analysis of the Box-Behnken Experimental Design 
formulations 
 
Figure 4.6a exhibits the release profiles of DPH from all the design formulations in PBS (pH 
6.8, 37°C). Drug release results of DPH from the design formulations essentially confirmed 
those of the preliminary results where the formulations containing a higher quantity of PA 
6,10 provided more linear release profiles of DPH. This trend was noted for most of the 
formulations. F1 and F7 displayed the most linear release profiles. Release from PBS (pH 
6.8, 37°C) was more desirable than the release from SGF (pH 1.2, 37°C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b) a) 
y=34.81x 
R2= 0.966 
 
y=28.67x 
R2= 0.995 
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Figure 4.6: Drug release profiles of a) DPH, b) PMZ and c) RDH from the Box-Behnken 
design formulations in PBS (pH 6.8, 37°C). 
 
PMZ release from the middle layer was linear in most of the formulations as was noted in the 
preliminary studies. This was due to the uniform area of the surfaces that are exposed to the 
dissolution medium which allows for a constant diffusion path length. Hence, this is 
conducive to a uniform flux and thus a constant release of the drug over a time interval (Yang 
and Fassihi, 1997; Abdul and Poddar, 2004). Figure 4.6b displays the drug release profiles of 
PMZ from the design formulations. Release from the outer s-PLGA layer proved to be the 
most challenging in providing linear release of RDH (Figure 4.6c), F7 showed the most linear 
b) 
c) 
a) 
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release profile of RDH that confirms the results from the preliminary drug release results; a 
lower s-PLGA to PEO ratio evidently appeared to have generated more favorable results. A 
possible mechanism for this may be that the s-PLGA functioned as a controlling mechanism 
by retarding the swelling of PEO in a more uniform manner. 
 
4.3.2. Evaluation of rate constants computed from the design formulations 
 
4.3.4.1. DPH rate constants 
 
The average rate constants for each formulation are exhibited in Table 4.5. Following the 
scrutiny of k values computed for the design formulations it was discovered that F1 and F3 
displayed the most desirable rate constants relative to the ideal while F10, F13 and F16 
displayed the least desirable rate constants in PBS (pH 6.8, 37°C).  F1, F7 and F16 were 
observed to have more desirable rate constants in SGF (pH 1.2, 37°C). 
 
Table 4.5: Rate constants (k values) for the experimental optimization of TLT formulations. 
 k (SGF)±S.D.  k (PBS) ±S.D.  
Formulation Layer 1 (DPH) Layer 3(RDH) Layer 1 (DPH) Layer 3 (RDH) 
1 0.037 ± 0.0020 0.049 ± 0.0013 0.041 ± 0.0020 0.033 ± 0.0004 
2 0.046 ± 0.0002 0.040 ± 0.0010 0.043 ± 0.0040 0.051 ± 0.0026 
3 0.052 ± 0.0070 0.039 ± 0.0065 0.041 ± 0.0030 0.049 ± 0.0011 
4 0.052 ± 0.0080 0.039 ± 0.0020 0.042 ± 0.0003 0.055 ± 0.0042 
5 0.035 ± 0.0030 0.057 ± 0.0016 0.032 ± 0.0030 0.050 ± 0.0030 
6 0.043 ± 0.0070 0.058 ± 0.0018 0.046 ± 0.0030 0.052 ± 0.0059 
7 0.039 ± 0.0074 0.054 ± 0.0025 0.029 ± 0.0005 0.051 ± 0.0006 
8 0.031 ± 0.0050 0.051 ± 0.0019 0.029 ± 0.0003 0.047 ± 0.0035 
9 0.045 ± 0.0034 0.038 ± 0.0133 0.040 ± 0.0012 0.054 ± 0.0028 
10 0.047 ± 0.0006 0.050 ± 0.0003 0.051 ± 0.0025 0.045 ± 0.0028 
11 0.052 ± 0.0062 0.034 ± 0.0205 0.047 ± 0.0030 0.051 ± 0.0061 
12 0.053 ± 0.0025 0.024 ± 0.0029 0.040 ± 0.0035 0.049 ± 0.0021 
13 0.037 ± 0.0002 0.058 ± 0.0037 0.054 ± 0.0026 0.048 ± 0.0011 
14 0.030 ± 0.0016 0.052 ± 0.0021 0.047 ± 0.0042 0.051 ± 0.0006 
15 0.025 ± 0.0005 0.073 ± 0.0128 0.039  0.0010 0.050 ± 0.0021 
16 0.041 ± 0.0001 0.052 ± 0.0071 0.052 ± 0.0026 0.061 ± 0.0013 
17 0.048 ± 0.0148 0.046 ± 0.0018 0.042 ± 0.0028 0.055 ± 0.0003 
 
The analysis of k values obtained in accordance with DPH release from the TLT formulations 
revealed that an increase in PA6,10 concentration in the TLT correlated with a k value that 
was inclined towards the ideal value of 0.0417. However, the increase in PA6,10 was limited 
essentially to 300mg within the layer which allows for a more reasonable tablet size and 
therefore uncomplicated patient administration. Also, with regards to the ratio of PA6,10 to 
SS it was important to note that the polymer (PA6,10) ideally should comprise the bulk of the 
layer as the function of SS was to inhibit the initial burst release of drug. Hence, it was noted 
that formulations that were comprised of a large PA6,10 to SS ratio resulted in a more 
desirable k value for drug release. This may be attributed to the PA6,10 being capable of 
forming a more compact drug matrix which may be able to retard and control the release of 
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DPH in a more superior manner as mentioned in Chapter 3 during preformulation studies. 
Figure 4.7 contains typical contour plots depicting the relationship between the rate 
constants and polymer concentrations in the TLT matrix for the release of DPH in SGF (pH 
1.2, 37°C). 
 
 
Figure 4.7: Contour plots of the relationship between rate constant and polymer 
concentration for DPH release in SGF (pH 1.2, 37°C). 
 
4.3.4.2. RDH rate constants 
 
The average k values for each of the design formulation constants are displayed in Table 
4.5. Subsequent to analysis it was noted that F8 and F10 displayed the most desirable k 
values in comparison to the ideal while F1, F4 and F17 displayed the least desirable k values 
in PBS (pH 6.8, 37°C). F2, F3 and F4 displayed the most desirable k values while F6, F13 
and F15 displayed the least desirable rate constants in SGF (pH 1.2, 37°C). The analysis of 
rate constants obtained according to RDH release from the TLT formulations uncovered 
observations revealing that decreased concentrations of s-PLGA in the TLT were associated 
with a more desirable rate constant and a lower s-PLGA to PEO ratio exhibited a similar 
result. The reason for this detected behavior may be explained by the swelling of PEO which 
may provide a constant diffusion path length for RDH to be released as observed during 
preformulation in Chapter 3. The s-PLGA was rationalized to facilitate uniform swelling of 
PEO. Figure 4.8 contains typical contour plots illustrating the relationship between polymer 
concentration and rate constants for RDH release in SGF (pH 1.2, 37°C).  The plots illustrate 
the significant relationship between PEO and s-PLGA which result in desirable k values in 
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the range of 0.03-0.06 occurring with PEO quantities between 200mg to 350mg and s-PLGA 
quantities between 40mg and 50mg. 
 
 
Figure 4.8: Contour plots of the relationship between k values and polymer concentration for 
RDH release in SGF (pH 1.2, 37°C). 
 
4.3.5. Evaluation of correlation coefficients obtained from experimental design 
formulations 
 
4.3.5.1. DPH correlation coefficients 
 
The average R2 values for each of the design formulations accompanied by standard 
deviations are displayed in Table 4.6. In all cases N=2. With the essential aim of establishing 
the optimal inclination to linearity, the analysis of R2 values computed from the design 
formulations was indeed necessary. It was revealed that F1 and F9 displayed the most 
favorable R2 values while F5, F15 and F16 exhibited the least favorable R2 values in SGF 
(pH 1.2, 37°C). F1, F3 and F7 displayed the most favorable R2 values while F13 and F16 
exhibited the least favorable R2 values in PBS (pH 6.8, 37°C).  
 
Upon analysis, a similar pattern as with the rate constants was noted, that is a greater 
quantity of PA6,10 resulting in more linear profiles which is fundamentally in accordance the 
most desirable R2 values. The certain instances where a high PA6,10 quantity correlated with 
an unfavorable R2 value may be due to experimental or observational error. Figure 4.9 
displays vertical bar charts depicting the average R2 values of the experimental design 
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formulations for DPH release a) PBS (pH 6.8, 37°C) and b) SGF (pH 1.2, 37°C). The 
favorable behavior of the formulations in PBS (pH 6.8, 37°C) is clearly noticeable in the bar 
graphs. A greater tendency towards an R2 value of 1 was evident in PBS (pH 6.8, 37°C) as 
opposed to SGF (pH 1.2, 37°C).  Figure 4.10 is comprised of contour plots depicting the 
relationship between polymer quantities and R2 values.  It was observed that the desirable R2 
value range of 0.5-1 was achieved with PA6,10 quantities between 250 and 400mg and SS 
quantities between 50-150mg.  
 
Table 4.6: Correlation coefficients (R2 values) for the experimental optimization of TLT 
formulations. 
Formulation R2 (SGF) )±S.D.  R2 (PBS) )±S.D.  
Layer 1 (DPH) Layer 3 (RDH) Layer 1 (DPH) Layer 3 (RDH) 
1 0.984 ± 0.0132 0.704 ± 0.0172 0.938 ± 0.0313 0.606± 0.0527 
2 0.606 ± 0.0990 0.816 ± 0.0341 0.782 ± 0.0416 0.607± 0.0811 
3 0.622 ± 0.1430 -0.424 ± 0.0930 0.900 ± 0.0132 0.400± 0.0341 
4 0.388 ± 0.0220 -0.424 ± 0.0513 0.876 ± 0.0465 0.284± 0.0496 
5 -0.512 ± 0.3470 0.298 ± 0.0099 0.687 ± 0.0057 0.733± 0.0863 
6 0.384 ± 0.0370 0.631 ± 0.0254 0.629 ± 0.0331 0.438± 0.3385 
7 0.410 ± 0.0410 0.414 ± 0.1034 0.908 ± 0.0662 0.725± 0.0100 
8 0.808 ± 0.0540 0.057± 0.0084 0.849 ± 0.0522 0.679± 0.0672 
9 0.819 ± 0.0142 0.959± 0.2893 0.610 ± 0.0228 0.641± 0.0921 
10 0.326 ± 0.0104 0.681± 0.0054 0.690 ± 0.0706 0.275± 0.0577 
11 0.275 ± 0.0586 0.576± 0.0552 0.798 ± 0.0153 0.368± 0.1963 
12 0.659 ± 0.1380 0.565± 0.1613 0.896 ± 0.0129 0.653± 0.1009 
13 0.505 ± 0.0303 0.588± 0.0496 0.024 ± 0.1980 0.739± 0.0494 
14 -1.000 ± 0.0087 0.436± 0.1573 0.904 ± 0.0482 0.695± 0.0054 
15 -1.144 ± 0.0513 0.818± 0.2563 0.938 ± 0.0317 0.782± 0.1742 
16 0.599 ± 0.0419 0.670± 0.1786 -0.403 ± 0.0422 0.594± 0.0578 
17 -0.481 ± 0.007 0.247± 0.0392 0.528 ± 0.1564 0.433± 0.0912 
 
 
 
Figure 4.9: Vertical bar chart displaying the average correlation coefficients (R2) of the 
design formulations in a) PBS (pH 6.8, 37°C) and b) SGF (pH 1.2, 37°C),  (N=2). 
 
 
a) b) 
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Figure 4.10: Contour plots depicting the relationship between the polymer mixtures and the 
R2 values of DPH release from the design formulations in PBS (pH 6.8, 37°C). 
 
4.3.5.2. RDH correlation coefficients 
 
F5, F7 and F13 displayed the most favorable R2 values while F4 and F10 displayed the least 
favorable R2 values in PBS (pH 6.8, 37°C). F2 and F9 exhibited the most desirable R2 values 
while F3 and F4 exhibited the least desirable R2 values in SGF (pH 1.2, 37°C). As previously 
mentioned, this fits in with the pattern observed for the rate constants. A higher PEO to s-
PLGA ratio resulted in more desirable R2 values. The opposite was noted for lower PEO to s-
PLGA. This is owed to the resulting R2 values being very distant to the ideal. Figure 4.11 
includes the contour plots illustrating the relationship between polymer concentrations and R2 
values for RDH release in PBS (pH 6.8, 37°C) which further substantiates the optimal R2 
values in the range of 0.8-1 being achieved within the polymer mixtures containing 300-
350mg PEO and 0-50mg s-PLGA.  
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Figure 4.11: Contour plots depicting the relationship between the polymer mixture and the 
R2 values of the release of RDH from the design formulations in PBS (pH 6.8, 37°C). 
 
4.3.6. Assessment of the experimental and fitted response values calculated for the 
experimental optimization of TLT formulations 
 
The measured responses obtained from the design of experiments were plotted relatively 
against the fitted responses obtained. The experimental versus fitted k values plots for DPH 
in PBS (pH 6.8, 37°C) and SGF (pH 1.2, 37°C) are displayed in Figures 4.12a and b 
respectively. R2 values for the comparative responses were computed to be 0.696 and 0.593 
in SGF (pH 1.2, 37°C) and PBS, respectively. The experimental versus fitted k values plots 
for RDH in SGF (pH 1.2, 37°C) and PBS are displayed in Figures 4.12c and d. R2 values for 
the comparative responses were calculated to be 0.772 and 0.715 in SGF (pH 1.2, 37°C) 
and PBS (pH 6.8, 37°C), respectively.  
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Figure 4.12: Regression plots for rate constants (k) for a) DPH in SGF (pH 1.2, 37°C), b) 
DPH in PBS (pH 6.8, 37°C), c) RDH in SGF and d) RDH in PBS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) b) 
c) d) 
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Figure 4.13: Regression plots for correlation coefficients (R2 values) for a) DPH in SGF (pH 
1.2, 37°C) b) DPH in PBS (pH 6.8, 37°C), c) RDH in SGF (pH 1.2, 37°C) and d) RDH in PBS 
(pH 6.8, 37°C). 
 
The plots for experimental versus fitted R2 values for DPH in SGF (pH 1.2, 37°C) and PBS 
(pH 6.8, 37°C) are displayed in Figures 4.13a and b. Correlation coefficients of 0.719 and 
0.670 were demonstrated for SGF (pH 1.2, 37°C) and PBS (pH 6.8, 37°C) respectively. 
Figures 4.13c and d illustrate the experimental versus fitted plots for R2 values of RDH in 
SGF (pH 1.2, 37°C) and PBS (pH 6.8, 37°C) with correlation coefficients of 0.532 and 0.597 
being obtained for SGF (pH 1.2, 37°C) and PBS  (pH 6.8, 37°C) respectively.  
 
4.3.7. Evaluation of residual plots for optimization and subsequent response 
optimization of the TLT matrices 
 
Residuals plots may be employed to analyze the fit of regression models in a Box-Behnken 
design. These plots can be defined as measuring the variation between the actual observed 
responses and the predicted responses. Figures 4.14, 4.15, 4.16, 4.17, 4.18, 4.19, 4.20 and 
4.21 display the residual plots for the analysis of the Box-Behnken Experimental Design.  
 
a) b) 
d) c) 
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Figure 4.14: Diagnostic plots showing residual plots for rate constant (k) of DPH in PBS (pH 
6.8, 37°C). 
 
 
 
Figure 4.15: Diagnostic plots indicating the residual plots for rate constant (k) of RDH in PBS 
(pH 6.8, 37°C). 
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Figure 4.16: Diagnostic plots indicating the residual plots for correlation coefficients (R2 
values) for DPH in PBS (pH 6.8, 37°C). 
 
 
 
Figure 4.17: Diagnostic plots indicating the residual plots for correlation coefficients (R2 
values) for RDH in PBS (pH 6.8, 37°C). 
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Figure 4.18: Diagnostic plots indicating the residual plots for rate constants (k) for DPH in 
SGF (pH 1.2, 37°C). 
 
 
Figure 4.19: Diagnostic plots indicating the residual plots for rate constants (k) for RDH in 
SGF (pH 1.2, 37°C). 
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Figure 4.20: Diagnostic plots indicating the residual plots for correlation coefficients (R2 
values) for DPH in SGF (pH 1.2, 37°C). 
 
 
Figure 4.21: Diagnostic plots indicating the residual plots for correlation coefficients (R2 
values) for RDH in SGF (pH 1.2, 37°C). 
 
On analysis of k (Figures 4.14, 4.15, 4.16 and 4.17) and R2 values (Figures 4.18, 4.19, 4.20 
and 4.21) for drug release from the two outer layers, it was found that there was an 
indiscriminate distribution of data. The scatter of data observed in the residual versus fitted 
value plots showed a random arrangement of data indicating that the fit of the data to the 
linear regression model was of a satisfactory nature. The residual histograms exhibited 
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nearly bell-shaped curves with the exception of a few. The presence of a bell-shaped curve 
indicates a relatively normal distribution of data. If this shape is not observed, it is indicative 
of an aspect of the data that is not accounted for in the model which needs to be identified for 
a better outcome. The residual versus observation order plots showed indiscriminate 
fluctuations in relation to the centre line which suggests that the error terms did not correlate 
amongst one another. The regression equations generated for the two responses for each 
layer in both PBS (pH 6.8, 37°C) and SGF (pH 1.2, 37°C) are demonstrated below for k 
value (DPH, PBS (pH 6.8, 37°C), Equation 4.2), k value (DPH, SGF (pH 1.2, 37°C), Equation 
4.4), k value (RDH, PBS (pH 6.8, 37°C), Equation 4.3), k value (RDH, SGF (pH 1.2, 37°C), 
Equation 4.5), R2 value (DPH, PBS (pH 6.8, 37°C), Equation 4.6), R2 value (DPH, SGF (pH 
1.2, 37°C), Equation 4.8), R2 value (RDH, PBS (pH 6.8, 37°C), Equation 4.7) and R2 value 
(RDH, SGF, Equation 4.9). 
 
  
[ ] [ ] [ ] [ ]
[ ][ ] [ ][ ]
[ ][ ] [ ][ ]PA6,10PEO4398.0SSPLGAs2778.0
PA6,10PLGAs3455.0PEOPLGAs1059.0
SS2258.0PA6,101035.0PEO0867.0PLGAs0046.0
+−−
−−−+
+−−−=k
                  
                                                                                                                              Equation 4.2 
         
  
[ ] [ ] [ ] [ ]
[ ][ ] [ ][ ]
[ ][ ] [ ][ ]PA6,10PEO0893.0SSPLGAs0024.0
PA6,10PLGAs4343.0PLGAs1353.0
SS0388.0PA6,101236.0PEO0217.0PLGAs1359.0
−−−
−−−+
+++−=
PEO
k
                   
                                                                                                                              Equation 4.3 
 
     
[ ] [ ] [ ] [ ]
[ ][ ] [ ][ ]
[ ][ ] [ ][ ]PA6,10PEO6487.0SSPLGAs3387.0
PA6,10PLGAs7697.0PLGAs0526.0
SS1327.0PA6,101756.0PEO0762.0PLGAs1364.0
+−+
−+−+
+−−−−=
PEO
k
               
                                                                                                                              Equation 4.4 
         
                
[ ] [ ] [ ] [ ]
[ ][ ] [ ][ ]
[ ][ ] [ ][ ]PA6,10PEO819.0SSPLGAs557.0
PA6,10PLGAs216.1PLGAs058.0
SS058.0PA6,10397.0PEO125.0PLGAs311.0
−−−
−−−+
−++−−=
PEO
k
 
                                                                                                                              Equation 4.5 
                
                
[ ] [ ] [ ] [ ]
[ ][ ] [ ][ ]
[ ][ ] [ ][ ]PA6,10PEO470.18SSPLGAs808.9
PA6,10PLGAs922.29PLGAs280.5
SS318.3PA6,10990.5PEO946.0PLGAs927.6R2
+−+
−+−−
+−−−−=
PEO            
                                                                                                                                                           Equation 4.6 
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[ ] [ ] [ ] [ ]
[ ][ ] [ ][ ]
[ ][ ] [ ][ ]PA6,10PEO930.4SSPLGAs318.5
PA6,10PLGAs973.8PLGAs637.2
SS407.0PA6,10306.2PEO912.1PLGAs448.3R2
−−−
−−−−
−++−=
PEO  
                                                                                                                                                          Equation 4.7
                    
[ ] [ ] [ ] [ ]
[ ][ ] [ ][ ]
[ ][ ] [ ][ ]PA6,10PEO469.18SSPLGAs023.13
PA6,10PLGAs610.39PLGAs760.9
SS220.2PA6,10553.9PEO186.2PLGAs464.6R2
+−+
−+−−
−−+−−=
PEO           
                                                                                                                                                          Equation 4.8 
 
               
[ ] [ ] [ ] [ ]
[ ][ ] [ ][ ]
[ ][ ] [ ][ ]PA6,10PEO83.1SSPLGAs30.18
PA6,10PLGAs67.13PLGAs12.11
SS69.3PA6,1066.0PEO02.0PLGAs66.7R2
+−−
−−−−
+++−=
PEO            
                                                                                                                              Equation 4.9 
 
4.3.8. Response Optimization 
 
Optimization was executed using Minitab®, V15 (Minitab® Inc, Pennsylvania, USA). The TLT 
was optimized in accordance with the dependent variables (measured responses) of k values 
and R2 values. The values of the measured responses were targeted within the limits 
according to those of the ideal formulation outlined previously. Figures 4.22 and 4.23 exhibit 
the ultimate optimization plots for rate constants in SGF (pH 1.2, 37°C) and PBS (pH 6.8, 
37°C) displaying a composite desirability of 88.23%.  
 
Table 4.7: Targeted response values for TLT optimization in both SGF (pH 1.2, 37°C) and 
PBS (pH 6.8, 37°C). 
Response Lower Target Upper 
k value 0.0350 0.0417 0.0500 
R2 value 0.7000 1.0000 1.0000 
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Figure 4.22: Optimization plots for rate constants in SGF (pH 1.2, 37°C), *1KDG refers to the 
rate constant for DPH in SGF (pH 1.2, 37°C), **2KPG refers to the rate constant for PMZ in 
SGF (pH 1.2, 37°C) and ***3KRG refers to the rate constant for RDH in SGF (pH 1.2, 37°C) . 
 
 
Figure 4.23: Optimization plots for rate constants in PBS (pH 6.8, 37°C), *1KDP refers to the 
rate constant for DPH in PBS, **2KPP refers to the rate constant for PMZ in PBS and 
***3KRP refers to the rate constant for RDH in PBS. 
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4.3.9. In vitro assessment of the optimized TLT formulation 
 
The two established optimized formulations which were 217.27mg PA6,10: 124.70mg SS 
and 59.47mg s-PLGA: 298.56g PEO in PBS (pH 6.8, 37°C)) and 257.92mg PA6,10: 92.98mg 
SS and 50mg s-PLGA: 300mg PEO in SGF (pH 1.2, 37°C) were subjected to the same in 
vitro dissolution conditions as those from the experimental design. Each optimized 
formulation was tested in both SGF (pH 1.2, 37°C) and PBS (pH 6.8, 37°C) once again for a 
comprehensive analysis.  
 
After further analysis it was discovered that a combination of the two optimized formulations 
provided superior linear release in both SGF (pH 1.2, 37°C) and PBS (pH 6.8, 37°C) which 
was more desirable since having one formulation that is capable of providing linear release in 
both gastrointestinal environments would fundamentally be more feasible and simple.  
 
The optimal formulation was found to be 257.92mg PA6,10: 92.08mg SS and 59.47g s-
PLGA: 298.56mg PEO with the middle layer having a constant quantity of 350mg PEO.  This 
was further confirmed by subjecting the formulation to dissolution in a USP 32 Apparatus 3 
(Bio-Dis II Release Rate Tester, Vankel Industries). This allowed for automatic changes in 
pH environments essentially simulating the potential gastrointestinal transit of the TLT. 
Figures 4.24a, b and c demonstrate the drug release profiles achieved from the optimized 
formulation. Table 4.8 exhibits the experimental versus predicted responses computed for 
the optimized TLT formulation. 
 
Table 4.8: The predicted versus experimental values of the measured responses after 
optimization. 
Response Predicted value Experimental value Desirability 
k value DPH (SGF) 0.0482 0.0422 ± 0.005 80.40% 
k value DPH (PBS) 0.0401 0.0454 ± 0.012 97.42% 
R2 value DPH (SGF) 0.7527 0.8309 ± 0.017 88.76% 
R2 value DPH (PBS) 0.9310 0.8354 ± 0.024 89.73% 
k value RDH (SGF) 0.0377        0.0481 ± 0.020 90.29% 
k value RDH (PBS) 0.0477 0.0601 ± 0.008 53.18% 
R2 value RDH (SGF) 0.5297 0.7407 ± 0.035 78.62% 
R2 value RDH (PBS) 0.6862 0.4046 ± 0.023 58.96% 
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Figure 4.14: Drug release profiles of a) DPH; b) RDH and c) PMZ from the optimized TLT 
formulation (N=3). 
 
4.4. Concluding Remarks 
 
TLT matrices were prepared and optimized according to a Box-Behnken Experimental 
Design. The influence that the independent variables had on the measured responses was 
a) 
b) 
c) 
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analyzed, resulting in the statistical establishment of an optimized formulation. The optimized 
formulation displayed a satisfactory near linear release of the model drugs. The chosen 
experimental design proved to be satisfactory yet not optimal for the complex facets of the 
said TLT. Further research should focus on establishing a more fitting and comprehensive 
statistical analysis for the intricate nature of the TLT.  
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CHAPTER 5  
CHARACTERIZATION AND FURTHER INTROSPECTIVE EVALUATION OF THE 
OPTIMIZED TRIPLE-LAYERED TABLET FORMULATION 
 
5.1. Introduction 
 
The physicomechanical properties of a drug delivery system may have a significant effect on 
drug release behavior. Therefore, it is necessary to assess the physicomechanical 
characteristics, and the effects of such characteristics on physicochemical and drug release 
performance (Tiwari and Rajabi-Siahboomi, 2008). By assessing the overall structural 
characteristics of a formulation, it is possible to gauge the effects of said characteristics on 
drug release potential and stability of the formulation.  
 
The stability of the TLT upon storage and under in vivo conditions is extremely significant as 
it determines whether the TLT is a feasible system to develop. The presence of pores within 
the TLT structure may vastly affect the drug release potential and is therefore another 
important analysis that needs to be performed. The physical behavior of the drug delivery 
system in the gastrointestinal environment is also a factor that needs to be determined as it 
may affect the patient tolerability of the system. When developing such a drug delivery 
system, it is necessary to gauge the versatility of drug release capabilities. It would be ideal, 
in this instance, that the drug delivery system be capable of acting as a matrix to a variety of 
drugs with various structures. 
 
 Subsequent to the design and optimization of the TLT, the matters summarized in this 
Chapter were further characteristic studies performed to ascertain the flexibility and overall 
behavior of the optimized TLT formulation. To begin with, the most logical approach was 
established to be the determination of superiority in drug release of the TLT to the 
conventional (commercial) drug products in an in vitro setting. This comparison was 
performed along with various other investigations, namely, Brinell Hardness Number 
evaluation, Scanning Electron Microscopy (SEM) imaging, porosity analysis and Magnetic 
Resonance Imaging (MRI). Another fundamental investigation that was conducted was the 
application of a therapeutic drug treatment regimen to the optimized TLT formulation. 
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5.2. Materials and Methods 
 
5.2.1. Materials 
 
Atenolol (ATN) and acetylsalicylic acid (ASA) were purchased from Sigma Chemical 
Company (St Louis, MO, USA). Simvastatin (SMV) was received as a gift sample from 
Adcock-Ingram (Johannesburg, South Africa). SLEEPEZE-PM®, Ranihexal® and Phenergan® 
were purchased from Parklane Hospital Pharmacy (Johannesburg, South Africa). All other 
reagents used were of analytical grade. 
 
5.2.2.1. Brinell Hardness Number evaluation of the optimized TLT formulation 
 
Matrix hardness evaluation of the optimized TLT formulation was performed as a function of 
Brinell Hardness Number (BHN) as per the parameters described in Chapter 3, section 
3.2.2.10. This was determined to assess the robustness of the TLT. 
 
5.2.2.2. Morphological surface structure imaging of the optimized TLT formulation 
employing Scanning Electron Microscopy 
 
Scanning Electron Microscopy (SEM) was carried out using a Phenom scanning electron 
microscope (FEI Company, Hillsboro, Oregon, USA) was employed to produce imaging of 
the PA 6,10 layer surface  for a holistic characterization and investigation for the presence of 
pores.  
 
5.2.2.3. Porosity analysis of the PA6,10 layer of the optimized TLT formulation 
 
Porosity analysis was conducted as a supplementary investigation to determine the presence 
of pores and pore size within the PA6,10 layer of the optimized TLT formulation. The 
rationale for this analysis is the untoward unhomogenous pores that might develop after 
compression (Wu et al., 2005). Surface area and porosity studies were conducted using a 
micromeritics ASAP analyzer (Micromeritics ASAP 2020, GA, USA). The procedure involved 
the degassing of samples prior to analysis. Degassing functions as a preparation stage to 
condition the sample to the appropriate state for analysis. A dissected section of the PA6,10 
layer was placed in the sample tube for analysis. 
 
5.2.2.4. In vitro dissolution testing on SLEEPEZE-PM®, Ranihexal®and Phenergan® 
 
In order to authenticate the results achieved by the optimized TLT formulation, it was 
necessary to draw a comparison in drug release behaviour between the TLT and the 
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conventional tablets available. The tablets selected were SLEEPEZE-PM® containing 
diphenhydramine (DPH), Ranihexal® containing ranitidine (RDH) and Phenergan® containing 
promethazine (PMZ). In vitro drug release studies were performed on the tablets using a 
USP 25 rotating paddle method in a dissolution apparatus (Caleva Dissolution Apparatus, 
model 7ST; G.B. Caleva Ltd., Dorset, UK) at 50rpm with 900mL simulated gastric fluid (SGF) 
(pH 1.2, 37°C) and 900mL phosphate-buffer solution (PBS) (pH 6.8; 37°C). A stainless steel 
mesh was used in the dissolution vessels in order to prevent the formulations from floating. 
Samples of 5 mL were drawn at pre-determined time intervals over a 24 hour period. 
 
5.2.2.5. Application of a therapeutic drug regimen to the optimized TLT formulation 
 
Three cardiovascular related drugs were selected for evaluating the flexibility of the 
optimized TLT formulation. Atenolol (ATN) which is a beta-blocker used to treat hypertension 
was selected for incorporation into the PA6,10 outer layer; aspirin (ASA) which is used as an 
anticoagulant in heart disease was selected for incorporation into the middle PEO layer and  
simvastatin (SMV) which is an antihyperlipidaemic drug was selected for incorporation into 
the s-PLGA outer layer. These drugs were chosen due to the high frequency with which they 
are used in conjunction with each other in cardiovascular related treatment regimens. 
Therefore a dosage form in which they all may be administered in a single dose would 
essentially be very beneficial in terms of patient compliance.  
 
Table 5.1 indicates the therapeutic quantities incorporated in to the TLT formulation. In vitro 
drug release studies were performed as described in Chapter 5, section 5.2.2.4. Ultraviolet 
(UV) spectrophotometry was employed to analyze the dissolution samples. 
   
Table 5.1: Quantities of drug actives incorporated in to TLT for the evaluation of drug release 
of therapeutic regimen. 
Drug Layer 1 (PA6,10) Middle layer (PEO) Layer 3 (s-PLGA) 
ATN 50mg - - 
ASA - 100mg - 
SMV - - 40mg 
 
5.2.2.6. Comparative in vitro dissolution analysis between the conventional 
therapeutic regimen formulations and the release of therapeutic regimen drugs from 
the optimized TLT formulation 
 
In order to confirm the superior release of ATN, SMV and ASA from the optimized TLT 
formulation, conventional drug products Tenormin® 50; DISPRIN CV®100 and Adco-
Simvastatin 40 were subjected to the equivalent in vitro dissolution studies as the optimized 
TLT formulation mentioned in Chapter 3, section 3.2.2.7. Calibration curves were constructed 
by preparing a stock solution which was serially diluted to prepare five standard solutions 
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employing grade A volumetric flasks. Linear curves were plotted as absorbance versus 
concentration (mg/mL).  
 
5.2.2.7. Benchtop Magnetic Resonance Imaging (MRI) of TLT performance 
 
A magnetic resonance system with digital MARAN-i System configured with a DRX2 HF 
Spectrometer console (Oxford Instruments Magnetic Resonance, Oxon, UK) equipped with a 
compact 0.5 Tesla permanent magnet stabilized at 37oC and a dissolution flow through cell 
was employed for the viewing of the mechanical behaviors of the matrices. . The image 
acquisition parameters are depicted in Table 5.2.  
 
Table 5.2: Image acquisition parameters applied during magnetic resonance imaging using 
MARAN-iP. 
S. No. Parameter Value 
1 Imaging protocol FSHEF 
2 Requested gain (%) 4.17 
3 Signal strength 68.92 
4 Average 2 
5 Matrix size 128 
6 Repetition time (ms) 1000.00 
7 Spin Echo Tau (ms) 6.80 
8 Image acquired after 60min 
9 Total scans 64 
 
After duly configuring, optimizing the shims and probe tuning, the cone-like lower part of the 
cell was filled with glass beads to provide laminar flow at 16mL/min of the solvents 
employed. The matrices were placed in position each time within the cell which in turn was 
positioned in a magnetic core of the system and magnetic resonance images were acquired 
every 30 minutes over 12 hours with MARAN-iP version 1.0 software. The image was 
acquired after setting the frequency offset and testing gain employing RINMR version 5.7 
under continuous solvent flow conditions. MARAN-iP software comprises image acquisition 
software and image analysis software. 
 
5.3. Results and Discussion  
 
5.3.1. Assessment of BHN 
 
The optimized TLT formulation was found to have a BHN of 13.63±0.009N/mm2 which 
correlated well with the previous hardness patterns and drug release behavior. The 
mechanical strength of the TLT is significant in order to assess the stability of the TLT 
against fracture upon agitation. This also confirmed the robust nature of the TLT. Upon 
physical handling and observation of the TLT it was virtually impossible to crack the surface 
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of the compressed TLT structure which further supported the mechanical strength of the 
optimized TLT.  
 
5.3.2. SEM images depicting the PA6,10 layer surface of the TLT 
 
SEM images of the PA6,10 layer showed irregular surfaces with minimal pores. The lack of 
pores observed on a surface image was found to be desirable. This is due to the possibility 
that the presence of pores after compression may alter the release of drug from the layer. 
The irregular surface may be attributed to the crystalline nature of PA6,10 at room 
temperature (25°C) which may have resulted in uneven compression and irregular 
distribution of the layer. The presence of such irregularities did not appear to significantly 
affect the release of drug from the layer. The reason for the lack of interaction may be the 
unhindered and uniform erosion of the PA6,10 layer upon dissolution irrespective of irregular 
surface. Upon interaction of the dissolution medium, the relaxation of PA6,10 in the layer 
may cancel out the irregular surfaces thereby resulting in uniform erosion and drug release.  
Figures 5.1a and b are SEM images obtained on analysis of the surface of the PA6,10 layer.  
 
        
Figure 5.1: Typical SEM images of a) the PA6,10 layer of the TLT at a lower magnification  
depicting irregular surfaces and b) the PA6,10 layer of the TLT at a greater magnification. 
 
a) b) 
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5.3.3. Porosity analysis     
Porosity analysis was conducted in order to determine the volume of distribution of pores if 
pores were found to be present in the optimized TLT. Pore size was also investigated. Table 
5.3 shows the resultant values subsequent to analysis using the Barret, Joyner and Halenda 
Method (BJH).         
             
Table 5.3: Assessment of pore volume and pore size of the TLT. 
Parameter Value 
Pore Size 
 
Adsorption average pore width 99.7681Å 
BJH adsorption average pore diameter 163.958Å 
BJH desorption average pore diameter 141.604Å 
Pore Volume 
 
BJH Adsorption cumulative volume of pores 
between 17.000Å and 3000.000Å diameter 
 
 
0.013191cm³/g 
BJH Desorption cumulative volume of pores 
between 17.000Å and 3000.000Å diameter 
0.013085cm³/g 
 
It was discovered that the pores contained in the TLT were chiefly mesoporic within the sizes 
of 99.7681Å and 163.958Å in diameter. No micropores were identified. The total pore volume 
ranged between 0.0065 and 0.0132cm³/g indicating a decreased pore volume which was 
desirable. This is due to the variable influence on drug release behavior that may occur in the 
presence of large pores. Therefore the lack of large pores is advantageous so as to not 
hinder drug release behavior. 
 
5.3.4. Comparative analysis of drug release behavior from conventional tablets 
SLEEPEZE-PM®, Ranihexal®and Phenergan®   and optimized TLT formulation   
 
In vitro dissolution results revealed that the optimized formulation profile depicted a 
significant superior release of DPH, PMZ and RDH as compared to the respective 
conventional tablets.  The optimized TLT achieved extended controlled release of all three 
drugs over 24 hours while the disintegration times of SLEEPEZE-PM® tablets, Ranihexal® 
tablets and Phenergan® tablets were approximately 1 hour, 1 hour and 30 minutes 
respectively. Figures 5.2a, b and c illustrate the drug release profiles of the conventional 
tablets.  
 
Furthermore, the erratic spiked concentrations due to an immediate burst release are also 
noted from the conventional products. This is exactly what the TLT aims to rectify wherever 
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applicable. By decreasing the initial rapid release of drug the TLT may thus decrease the 
potential of increased plasma drug levels that may lead to unwanted side-effects or toxicity.  
 
The rate constant (k) values calculated from the release profiles of SLEEPEZE-PM® tablets, 
Ranihexal® tablets and Phenergan® tablets were 1.3824, 1.3693 and 1.4701 respectively. 
The correlation coefficients (R2 values) generated from the release profiles were established 
to be 0.344, 0.366 and -0.340 respectively. The measured responses achieved by the 
conventional tablets further confirm the vast variance to controlled release patterns. This 
unmistakeable difference solidifies the controlled release capability of the TLT. 
 
 
 
Figure 5.2: Drug release profiles from conventional tablets a) SLEEPEZE-PM®, b) 
Phenergan® and c) Ranihexal® in PBS (pH 6.8, 37°C). 
 
 
 
 
 
 
a) b) 
  c) 
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5.3.5. Establishment of the efficacy of the TLT for the controlled delivery of a 
cardiovascular therapeutic drug regimen 
 
5.3.5.1. Construction of calibration curves 
 
Correlation coefficients (R2 values) were calculated to be more than 0.96 for all plots.  
Figures 5.3, 5.4 and 5.5 display the calibration curves prepared for ATN, ASA and SMV 
respectively in SGF (pH 1.2, 37°C) and PBS (pH 6.8, 37°C). 
 
 
Figure 5.3: Calibration curve for ATN in a) PBS (pH 6.8, 37°C) and b) SGF (pH 1.2, 37°C). 
 
  
Figure 5.4: Calibration curves for ASA in a) PBS (pH 6.8, 37°C) and b) SGF (pH 1.2, 37°C). 
 
    
Figure 5.5: Calibration curves for SMV in a) PBS (pH 6.8, 37°C) and b) SGF (pH 1.2, 37°C). 
a) b) 
a) b) 
a) b) 
y=3.8443x 
R2= 0.998 
y=3.8451x 
R2= 0.999 
y=2.7524x 
R2= 0.999 
y=2.612x 
R2= 0.999 
y=57.91x 
R2= 0.995 
y=57.106x 
R2= 0.996 
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5.3.5.2. Characterization of drug release behavior after the incorporation of ATN, ASA 
and SMV into the TLT 
 
Drug release results obtained after dissolution studies showed desirable linear or near linear 
release profiles of all three drugs. Table 5.4 contains the respective k values and R2 values 
obtained from the release of ATN, ASA and SMV from the optimized TLT formulation. 
Release of ATN from the TLT revealed that only half the loaded dose was released after 24 
hours in PBS (pH 6.8, 37°C) (Figure 5.6) while the entire loaded dose was released in SGF 
(pH 1.2, 37°C). The k values obtained for the release of ATN were 0.0219 in PBS (pH 6.8, 
37°C) and 0.0413 in SGF (pH 1.2, 37°C). The R2 values computed were 0.8851 and 0.9983 
IN PBS (pH 6.8, 37°C) and SGF respectively.  
  
Table 5.4: Measured responses for the release of therapeutic regimen from optimized TLT 
formulation (in all cases N = 3). 
Drug k values (SGF)  
± S.D. 
k values (PBS) 
 ± S.D. 
R2 values (SGF) 
± S.D. 
R2 values 
(PBS) ± S.D. 
ATN 0.0413 ± 0.0036 0.0219 ± 0.0025 0.9983 ± 0.0095 0.8851 ± 0.1074 
ASA 0.0423 ± 0.0005 0.0416 ± 0.0000 0.9343 ± 0.0267 0.8966 ± 0.0233 
SMV 0.0350 ± 0.0009 0.0363 ± 0.0004 0.9487 ± 0.0059 0.9358 ± 0.0472 
  
In terms of the release of ASA from middle PEO layer, a prolonged linear profile was 
obtained as displayed in Figure 5.7. Approximately 80% and 90% of the loaded dose was 
released after 24 hours in PBS (pH 6.8, 37°C) and SGF (pH 1.2, 37°C) respectively. The 
release of SMV from the s-PLGA outer layer displayed a similar linear extended release over 
24 hours as illustrated in Figure 5.8.  Near linear release profiles were noted in both SGF (pH 
1.2, 37°C) and PBS (pH 6.8, 37°C). The fundamental presence of solid evidence of a 
controlled release pattern of the three drugs from the TLT authenticates potential of the TLT 
to provide linear or near linear release of a variety of drugs. 
 
 
Figure 5.6: Drug release profile of ATN from optimized TLT formulation in SGF (pH 1.2, 
37°C) and PBS (pH 6.8, 37°C). 
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Figure 5.7: Drug release profile of ASA from optimized TLT formulation in SGF (pH 1.2, 
37°C) and PBS (pH 6.8, 37°C). 
 
 
 
Figure 5.8: Drug release profile of SMV from optimized TLT formulation in SGF (pH 1.2, 
37°C) and PBS (pH 6.8, 37°C). 
 
5.3.6. Comparative in vitro dissolution analysis between the conventional therapeutic 
regimen tablets and the release of ATN, ASA and SMV from the optimized TLT 
formulation 
 
Comparative results revealed that almost 100% of the drug was released in 0.5 to 1 hour for 
all three conventional tablets. Figures 5.9, 5.10 and 5.11 are drug release profiles of 
Tenormin® 50, DISPRIN CV®100 and Adco-Simvastatin 40 respectively. The rapid dissolution 
and burst release from the conventional tablets further supported the superiority of the TLT in 
terms of controlled and sustained release of the treatment regimen.  
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Figure 5.9: Drug release profiles of Tenormin® 50 in SGF (pH 1.2, 37°C) and PBS (pH 6.8, 
37°C). 
 
 
 
Figure 5.10: Drug release profiles of DISPRIN CV®100 in SGF (pH 1.2, 37°C) and PBS (pH 
6.8, 37°C). 
 
 
 
Figure 5.11: Drug release profiles of Adco-Simvastatin 40 in SGF (pH 1.2, 37°C) and PBS 
(pH 6.8, 37°C). 
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5.3.7. Benchtop Magnetic Resonance Imaging analysis of the optimized TLT 
formulation 
 
The pattern that was displayed throughout the images at different time points was the 
ultimate disappearance of the middle PEO and lower s-PLGA cores due to the progressive 
swelling that occurs and the disappearance of the inner core (black area in images) due to 
erosion and decreasing intactness of the upper PA6,10 layer in the dissolution medium over 
24 hours. A very clear succession is noticed (in Figure 5.12) with the increase in size of the 
lower two layers and the slight decrease in length and thickness of the upper layer. Figure 
5.12 displays the images of the TLT at various time points during progressive dissolution 
study. 
 
At 0.5 hours 6% of ATN was released, subsequently after an hour 8% of ATN was released. 
The data retrieved from MRI analysis shows a miniscule decrease in width and thickness of 
the outer layer between 0.5 and 1 hour. The change of size is associated with the 
disappearance of the core (black) of the PA6,10 layer. After 4 hours it was found that 
approximately 16% of ATN was released, this was associated with a marked variation in 
thickness of the PA6,10 layer. At 6 hours approximately 20% of ATN was released with a 
small change in thickness and width of the PA6,10 layer. At 10 hours, it was found that 26% 
of ATN was released with a noticeable decrease in thickness and width of the PA6,10 layer. 
After 12 hours, 30% was released with a further slight reduction of the PA6,10 layer. After 24 
hours, it was found that almost 50% of ATN was released with a large decrease of substance 
of the PA6,10 layer.  
 
At 0.5 hours 8% of ASA was released, which correlated with an increase in swelling and 
diameter of the middle PEO layer after 0.5 hours. After 1 hour, 10% of ASA was released 
noted with a further increase in diameter of the PEO layer. At 4 hours, almost 30% of ASA 
was released which was expected after a large increase in diameter swelling of the PEO 
layer. After 6 hours, 38% of ASA was released with a slight change of diameter from 4 hours. 
By 12 hours of dissolution time, almost 50% of ASA was released which was associated with 
a large increase in swelling and diameter of the PEO layer. At the end of 24 hours, 90% of 
ASA was released with a complete disappearance of the drug core and a large increase in 
diameter and swelling of the middle PEO layer. The release of SMV from the lower s-
PLGA/PEO layer followed a similar trend to that if ASA, this was also noted with the 
same pattern of swelling and increase in diameter of the layer over 24 hours.  
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Figure 5.12: MRI images at specific time points displaying the swelling and erosion 
characteristics of the TLT during dissolution in PBS (pH 6.8, 37°C). 
 
5.4. Concluding Remarks 
 
The holistic analysis of the optimized TLT formulation generated data that confirms the 
robustness of the TLT. Porosity analysis cancelled out the presence of undesirable 
micropores after compression. Furthermore the TLT displayed excellent capability for 
controlling and prolonging drug release as compared to the conventional antihistamine 
tablets selected. The significant application of the cardiovascular treatment regimen to the 
TLT articulated the flexibility of the TLT to different drug actives as well as achieving a 
significantly desirable release of the selected therapeutic drug regimen. Retrospective 
analysis indicates that the TLT may be very beneficial for the positive treatment of chronic 
conditions. 
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CHAPTER 6  
IN VIVO ASSESSMENT OF THE TRIPLE-LAYERED TABLET MATRIX IN THE LARGE 
WHITE PIG MODEL 
 
6.1. Introduction 
 
The use of appropriate animal models is undoubtedly an advantageous instrument for the 
determination of suitable therapeutic approaches for disease states in humans.  In vivo 
studies provide useful and relevant information on the biocompatibility of treatment types, 
tolerance, drug release behavior and plasma drug levels in a biological environment. Large 
white pigs were selected for the in vivo assessment of the triple-layered tablet (TLT) 
matrices.  
 
The Large White Pig model is undoubtedly advantageous over other animal models such as 
rats and mice for a more authentic validation and correlation of data analysis with human 
dosage.  One of the major reasons for this, apart from the larger size of the animal, is the 
allowance for more frequent blood sampling in pigs than in rats or mice which only allow for 
daily blood sampling intervals.  With more frequent blood sampling, a further comprehensive 
ability to identify and quantify altered or controlled drug release is essentially possible. It has 
been established that pigs have a similar gastrointestinal anatomy and physiology to humans 
(Oberle et al., 1994; Anderson et al., 2002). Furthermore, pigs are omnivores and their 
digestive characteristics would allow for a sufficient analogous comparison to humans. 
Another factor is the fact that pigs have been used in cardiovascular research (Crick et al., 
1998) which further confirms the application of such animals to in vivo analysis. The 
unequivocal widespread use of the pig model for drug delivery analysis ethically, further 
makes the selection of the Large White Pig model for the assessment of the TLT valid. Thus, 
this chapter involves the in vivo administration of the conventional drug products and the 
optimized TLT matrix formulation containing atenolol (ATN), aspirin (ASA) and simvastatin 
(SMV), for the assessment of the performance and tolerability of the TLT in the Large White 
Pig model.  
 
6.2. Materials and Methods  
 
6.2.1. Materials  
 
Solvents used for UPLC–MS/MS measurements were of UPLC grade, and all other reagents 
were of analytical grade. Double deionized water was obtained from a Milli-Q system, (Milli-
Q, Millipore, Johannesburg, South Africa). Control blank pig plasma was supplied by healthy 
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donors. HPLC grade Acetonitrile (ACN) was purchased from Microsep (Johannesburg, South 
Africa). Approval was received from the Animal Ethics Committee for the use of healthy 
Large White pigs in the in vivo release study. French gauge double lumen 35cm catheters 
(CS-28702) were purchased from Arrow Deutschland GmbH (Erding, Germany). Heparin 
vials (5000iu/5mL) and isotonic saline (1L) bags were purchased from Milpark Hospital 
Pharmacy (Johannesburg, South Africa). Pre-filters employed in the study were Acrodisc® 
13mm 0.2µm filters obtained from Life sciences (Johannesburg, South Africa). A BEH Shield 
RP18, 1.7µm, 2.1×100mm column was obtained from Waters Corporation (Milford, MA, 
USA).  
 
6.2.2. Methods  
 
6.2.2.1. Habituation of pigs prior to drug administration 
 
Healthy female Large White pigs were employed in the study. Pigs were housed in a farm 
unit and maintained under a 12 hour light dark cycle and fed a commercial diet. Figure 6.1 is 
a digital photograph showing the farm unit and housing of the pigs and the daily habituation 
process. Figure 6.4 displays the number of pigs required for the study. Habituation was 
necessary prior to in vivo studies in order to reduce the challenges associated with handling 
the animals for administration of formulations and blood sampling. The habituation involved 
visiting the animals twice a day and feeding them foods such as nuts and raisins.  
 
 
Figure 6.1: Farm unit, housing, daily habituation process of feeding and behavioural learning 
of the Large White Pig model. 
 
6.2.2.2. Surgical implantation of a chronic catheter into the left jugular vein of the pigs 
 
It was established that the most efficient way to sample blood from the pigs was to insert a 
catheter into the left jugular vein. The procedure was performed by the chief veterinarian and 
the supporting staff of the Central Animal Services (CAS) at the University of the 
Witwatersrand. This method was chosen as it caused the least amount of distress to the 
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animal as opposed to the previous blood sampling method which involved drawing of blood 
from the marginal ear vein of the pigs. The pigs were anaesthetized and then transported to 
the operating room and prepared for surgery. The preparation prior to surgery involved 
administering injections of antibiotics and analgesic agents and shaving of the operating site 
around the jugular vein. The animals were under anaesthesia and constant oxygen supply 
for the duration of the procedure which was performed under aseptic conditions. 
 
 
                
Figure 6.2: Digital photographs demonstrating a) Oxygen supply to animal after 
anaesthetization, b) Monitoring of heart rate, c) administration of injections and d) shaving of 
operating area. 
 
Figures 6.2a, b, c and d are digital photographs demonstrating the preparation for surgical 
procedure involved. In brief, the procedure began with an incision made to the left lateral 
aspect of the neck in order to expose the jugular vein. Once the vein was isolated, the 
catheter was inserted 10cm into the lumen of the vein. The lumen of the catheter was then 
sutured to the wall of the vein ensuring security. The remaining aspect of the catheter was 
then placed subcutaneously with the ports exposed via an outlet made around the dorsal 
area of the scapula. The wound was subsequently sutured and the ports were fastened with 
sutures to the skin. Figure 6.3a is a digital photograph of the 7 French gauge double lumen 
35cm catheter to be inserted into the left jugular vein during surgery. Following the procedure 
a ten day waiting period was necessary to allow the surgical wound to heal. During the 
waiting period, between each dosing of the animals and after each blood sample taken for 
the entire duration of the study, the catheters were flushed with 10mL of heparin in saline 
(5000i.u./L) twice a day to ensure that the catheters did not become blocked and that ease of 
blood sampling was achievable. 
b)a) 
b) a) 
c) d) c) 
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Figure 6.3: a) Catheter to be inserted into jugular vein, b) exposure of jugular vein for 
insertion, c) insertion of catheter into jugular vein and d) stitching up of wound with ports 
exposed for blood sampling. 
 
6.2.2.3. Administration of the conventional tablets to the Large White Pig model 
 
The dosing procedure was carried out in conjunction with the animal technicians at the CAS. 
The animals were injected with Ketamine HCl (40mg/kg) via the jugular vein catheter for 
anaesthetization. Once the animal was under anaesthesia it was moved to an open area and 
maintained under anaesthesia by topical procaine HCl (0.5%) and oxygenated.  The animal 
was then lifted into an upright position and an intragastric tube was inserted via the mouth of 
the animal down into the gastric region. The conventional tablets (Tenormin® 50; DISPRIN 
CV®100 and Adco-Simvastatin 40) were placed at the end of the tube and flushed down with 
a small quantity of water simultaneously. The animal was then laid down and carried to the 
pen where it was then closely observed for proper breathing until the anaesthesia wore off 
and it was conscious and mobile.  
 
6.2.2.4. Administration of the optimized TLT formulations to the Large White Pig model 
 
The procedure was carried out in the same way as that of the conventional dosage forms 
previously after a 3-day washout period allowing for more accurate and uncontaminated 
results. 
 
a) 
c) 
d) c) 
b) 
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6.2.2.5. Blood sample collection from the jugular vein catheter port of the Large White 
Pig model 
 
Blood samples for time point 0 hours were drawn prior to administration of the conventional 
dosage forms and TLT formulations to the pigs. Subsequent to administration and allowing 
for the anaesthesia to wear off, blood samples (5mL) were drawn from the jugular vein 
catheter ports at time intervals of 0; 2; 4; 6; 8; 10; 12; 16; 20 and 24 hours into heparin lined 
glass blood vials . Plasma was separated by centrifugation for 15 minutes at 3000rpm and 
stored at -70°C until analysis.  Figure 6.4 is a schematic diagram depicting the entire in vivo 
study sequential that was carried out.  
 
 
Figure 6.4: Schematic diagram depicting the number of pigs required and the steps involved 
during the in vivo studies. 
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6.2.2.6. Development of a method for sample analysis employing Ultra Performance 
Liquid Chromatography™   
 
Ultra performance liquid chromatography (UPLC) was the technique utilized to determine the 
concentration of the model drugs in the plasma retrieved at the different time points. It is a 
renowned technique employed for the separation of compounds by means of peak 
identification using stationary phase column particles with a size below 2.5µm (Dongre et al., 
2008). The fundamental concept is the running of samples through a column coupled with a 
PDA detector for the ultraviolet absorbance of the compounds. The utilization of column 
particles that are below 2.5µm results in a betterment of column efficiency. This subsequently 
leads to increased resolution of peaks and speedy analysis of samples (Jerkovich et al., 
2003, Krishnaiah et al., 2010).  
 
The Waters Acquity Ultra Performance Liquid Chromatography (UPLC) system (Waters, 
Milford, MA, USA) with a PDA detector was utilized in the study. The machine was equipped 
with a binary solvent manager that contained three lines (A, B1 and B2) for the flow of mobile 
phase solvents. Line A was for the exclusive use of inorganic solvents while lines B1 and B2 
were for the exclusive use of organic solvents such as methanol and ACN. Separation was 
achieved on an Acquity UPLC C18 column (50×2.1mm, i.d., 1.7µm particle size, Waters). A 
method for the simultaneous determination of ATN, ASA and SMV was investigated; this 
involved the selection of appropriate mobile phases, flow rate, wavelength and injection 
volume.  
 
After a series of attempts a suitable method to separate all three of the drugs was achieved. 
The mobile phases employed were 0.01%v/v orthophosphoric acid (OPA) and acetonitrile 
(ACN). An isocratic method with the ratio of 65:35 (OPA: ACN) proved to be the most 
adequate at separating the drugs. Table 6.1 displays the separation method selected for the 
three drugs. Diphenhydramine (DPH) was selected as the internal standard for quantification. 
Mobile phases were prepared and filtered through 0.22µm Millipore filters and placed on the 
machine with the appropriate solvent flow lines placed in the two mobile phases. The initial 
step to UPLC analysis is priming the machine which includes washing of the pumps and 
lines. Two types of washing occurred, a weak wash (90%V/V de-ionized water and 10%V/V 
ACN) and a strong wash (10%V/V de-ionized water and 90%V/V ACN). Once the priming 
process is complete (2 cycles of 10 minutes each), the column must be equilibrated to the 
selected separation method, this constitutes loading the method on to the software and 
allowing the mobile phases to flow through the column while the environment of the column 
is changed according to the method.  
 
Table 6.1: Method parameters for the simultaneous determination of ATN, ASA and SMV. 
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Parameter Condition 
Mobile Phase 0.01% OPA and ACN (65:35) isocratic gradient 
Flow rate 0.5mL/min 
Injection volume 5µL 
Wavelength 210nm 
Column Temperature 40°C 
 
6.2.2.7. Selection of a suitable method for extraction of ATN, ASA and SMV from 
plasma for UPLC analysis 
 
After various attempts at solid phase extraction (SPE) and liquid-liquid extraction for the 
adequate extraction of all three drugs from the plasma, SPE proved to be the least feasible 
option as it did not provide an adequately measurable result. As a result, the more optimal 
liquid-liquid extraction was further investigated. Liquid-liquid extraction involves the 
separation of different compounds according to their different affinities to solvents. The basic 
principle is the addition of a liquid solvent to another liquid solution containing the compound 
requiring separation (Muller et al., 2008). During method development, blank plasma was 
spiked with the three drugs and IS. The method that was developed involved the addition of 
ACN to plasma and subsequent centrifugation (Optima® LE-80K, Beckman, USA) and 
reconstitution. ACN was employed due to its effective deproteinating capability and the high 
solubility of all four drugs in ACN. Figure 6.5 is a schematic describing the sequential 
process of liquid-liquid extraction of ATN, ASA, SMV and DPH. 
 
 
Figure 6.5: Schematic diagram depicting the sequential process the liquid-liquid extraction 
procedure selected for the extraction of ATN, ASA and SMV from plasma. 
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6.2.2.8. Preparation of calibration curves and limit of quantification for ATN, ASA and 
SMV in plasma 
 
A standard stock solution (A) of 1mg/mL ATN, ASA and SMV was prepared. A second stock 
solution (B) of 0.1mg/mL was prepared from A. A micropipette was used to spike the blank 
plasma with specific quantities of ATN, ASA and SMV for calibration. A standard 
concentration of DPH was added to the different calibration samples followed by the 
extraction procedure described in Chapter 6, section 6.2.2.7. UPLC analysis was 
subsequently performed.  
 
6.2.2.9. UPLC analysis of drug release after the in vivo administration of Tenormin®, 
Adco-Simvastatin 40 and Disprin CV® and the optimized TLT formulation 
 
Once the suitable UPLC separation and plasma extraction procedures were optimized and 
subsequent to the preparation of calibration curves for the three drugs, it was necessary and 
feasible to run the plasma samples obtained from the in vivo animal study. The samples 
were prepared by spiking 500µL of plasma from each time point with a known concentration 
of IS and performing the extraction procedure mentioned in Chapter 6, section 6.2.2.7. Once 
the samples were prepared they were filtered in to ANSI482mL UPLC vials for analysis. 
UPLC analysis was carried out according to the UPLC separation method selected and 
mentioned in Chapter 6, section 6.2.2.6.  
 
6.3. Results and Discussion 
 
6.3.1. Behavior of pigs after insertion of a jugular vein catheter and after 
administration of the optimized TLT formulation 
 
On the actual day of the surgical procedure where the catheters were inserted in to the 
jugular vein of the pigs, the pigs displayed no changes in behavior from prior to the surgical 
procedure. Subsequent to the wearing off of anaesthesia the animals displayed the usual 
levels of activity and appetite as previously experienced. The quantity of time required for 
them to get back on their feet and walk around was not lengthy. The blood sampling 
procedure was not complex or time consuming, further proving the feasibility of the use of the 
catheter. The administration of the TLT showed no adverse effects to the pig substantiating 
the biocompatibility of the system orally. The pigs displayed normal behavior in terms of 
activity and appetite, blood sampling after administration of the TLT was normal as well.  
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6.3.2. Validation of selected method for UPLC analysis of plasma samples 
 
The method selected for plasma analysis proved to be ideal for the undisturbed simultaneous 
separation of ATN, ASA and SMV. The retention times obtained for ATN, ASA and SMV 
were approximately 0.45, 0.91 and 1.39 minutes respectively in ACN. Figure 6.6 is a 
chromatogram illustrating the peaks obtained for the three drugs at the different retention 
times.  
 
 
Figure 6.6: Chromatogram illustrating the separation peaks of ATN, ASA and SMV. 
 
Figure 6.7 is a three-dimensional (3D) plot depicting the three peaks of ATN, ASA and SMV 
further illustrating the appropriate separation of the three drugs. 3D inspection was useful in 
determining the most favorable absorption wavelength for all three drugs with minimal 
interference. DPH was selected as it was the only drug that did not overlap or disturb the 
other drug peaks. The retention time for DPH was found to be approximately 0.7 minutes. 
Figure 6.8 is a chromatogram showing the peaks obtained for all the drugs including DPH. 
The extraction method selected produced a drug recovery of 73%, 78% and 82% for ATN, 
ASA and SMV respectively. This was calculated by comparing the area of drug peaks 
generated in ACN to those generated from the plasma extraction method with the same 
concentration of drug.  
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Figure 6.7: 3D chromatogram of ATN, ASA and SMV. 
 
 
Figure 6.8: Chromatogram illustrating the separation peaks of ATN, ASA and SMV with DPH 
as the internal standard. 
 
6.3.3. Liquid-liquid extraction and assessment of UPLC chromatographic separation 
method in plasma 
 
Subsequent to the elucidation of the feasibility of the separation technique in ACN, it was 
then investigated for the separation of the drugs in plasma. A sample was prepared by 
spiking blank plasma with ATN, ASA, SMV and DPH. This mixture was then vortexed to 
allow for drug binding to the plasma. The extraction procedure described previously was then 
followed and the sample was injected for UPLC analysis.  After UPLC analysis, it was 
observed that the process proved to be adequate in providing separate peaks of all four 
drugs with slightly shifted retention times. Figure 6.9 is a chromatogram displaying the four 
drug peaks after plasma extraction.  
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Figure 6.9: Chromatogram displaying the separation peaks of ATN, ASA, SMV and DPH as 
the internal standard after plasma extraction. 
 
6.3.4. Calibration curves prepared for the quantitative analysis of ATN, ASA and SMV 
in plasma 
 
Figures 6.10a, b and c are the calibration curves obtained in plasma for ATN, ASA and SMV 
respectively. The calibration ranges selected were 0-50000ng/mL for all three drugs.    
   
 
 
Figure 6.10: a) ATN calibration curve in plasma; b) ASA calibration curve in plasma and c) 
SMV calibration curve in plasma. 
b) 
c) 
a) 
y=0.0005x 
R2=0.992 
y=0.0007x 
R2=0.996 
y=0.00005x 
R2=0.997 
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6.3.5. Assessment of in vivo drug release from Tenormin® 50; DISPRIN CV®100 and 
Adco-Simvastatin 40 
 
The ultimate aim of the in vivo study was to develop a comparison in drug release behavior 
between the conventional dosage forms and the optimized TLT formulation. An adequate 
comparison was necessary in vivo following the confirmation of a superior release from the 
TLT in vitro. Figure 6.11a, b and c contains the drug release profiles of Tenormin® 50; 
DISPRIN CV®100 and Adco-Simvastatin 40 respectively in plasma. For Tenormin® 50 it was 
noted that there was an initial significant ascension of plasma concentration after 2 hours, 
with peak plasma concentrations (Cmax= 816ng/mL) being reached at approximately 4 hours. 
This was followed by a swift reduction of plasma concentration for a further 8 hours.   
 
With DISPRIN CV®100, a similar trend was observed with an increase of plasma 
concentration until a Cmax of 2439ng/mL was reached at 8 hours followed by a steady 
descent of plasma concentration. The Adco-Simvastatin 40 release profile displayed much 
more miniscule plasma concentrations as compared to those of the previous two 
conventional tablets. The Cmax of 13.5ng/mL was reached at 6 hours after administration.  
 
Thus it can be confirmed that for all three conventional tablets, most of the drug was 
released by an initial burst before 8 hours after administration. This may due to the lack of 
controlling mechanisms present in the conventional tablets which are compressed powders 
of the drugs in question coupled with formulation excipients.  Although large standard 
deviations were noticed, the pattern of drug release was found to be consistent. 
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Figure 6.11: Plasma drug concentration profile depicting the release behavior over 24 hours 
of a) Tenormin® 50; b) DISPRIN CV®100 and c) Adco-Simvastatin 40 (N=5). 
 
a) 
b) 
c) 
Tenormin®50 
DISPRIN CV®100 
Adco-Simvastatin 40 
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6.3.6. Assessment of in vivo drug release from the optimized TLT formulation 
 
The stark comparative difference in drug release profiles between the conventional tablets 
and the optimized TLT formulation was immediately noted as illustrated in Figures 6.12a, b 
and c. With ATN, a gradual release of drug was noted at the onset. This steady increase in 
plasma concentration reached a Cmax of 4443ng/mL after 2 hours. The plasma levels 
subsequently decreased at the end of 24 hours. For ASA, a Cmax of 4195ng/mL was reached 
only at 24 hours, which was preceded by a steady increase in plasma concentration.  
 
A similar pattern was observed with SMV, Cmax (21ng/mL) was reached only 20 hours after 
administration. The very low therapeutic levels of the drugs that were reached may be due to 
the in vivo absorption and distribution characteristics of the drugs. According to literature, 
simvastatin has an overall low systemic oral bioavailaility (Bellosta et al., 2004) which is 
confirmable with the low Cmax of SMV that was obtained. Also, depending on the storage of 
the plasma that was collected, slight degradation of drug may have occurred even though 
temperature storage of -70°C was maintained.  
 
A prolonged release over a minimum 12 hours was achieved with all three drugs indicating a 
significant improvement on controlling plasma levels of each drug. The vast variance of TLT 
release profiles to that of the conventional tablets further authenticates the in vitro results 
obtained.  
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Figure 6.12: Comparative plasma drug concentration profiles of optimized TLT versus 
conventional tablets depicting drug release behavior over 24 hours of a) ATN versus 
Tenormin®50 ; b) ASA versus DISPRIN CV®  and c) SMV  versus Adco-simvastatin 40 (N=5). 
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6.4. Concluding Remarks 
 
The aim of the in vivo study was to assess the drug release capability of the TLT in 
comparison to the conventional tablets Tenormin® 50; DISPRIN CV®100 and Adco-
Simvastatin 40. The pig proved to be a feasible model for the study with the insertion of 
jugular vein catheters greatly improving the efficiency of the study. After completing the study 
and UPLC analysis of data, it was confirmed that the TLT formulation did in fact display a 
largely superior release profile in terms of sustained and controlled drug release to that of the 
conventional tablets. The TLT also displayed a lack of sharp plasma concentration 
fluctuations as compared to the conventional tablets. Although the release profile was less 
than desirable in comparison to in vitro study results, which may be attributed to first pass 
metabolism and erratic absorption of the drugs from the gastrointestinal tract, the TLT 
showed capability in controlling the plasma concentrations of the drugs. Further research 
may focus on developing more accurate analysis methods that may better qualify the TLT in 
vivo.  
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CHAPTER 7 
CONCLUSIONS AND RECOMMENDATIONS 
 
7.1. Conclusions 
 
It is evident that new developments allowing for improved and cheaper treatment outcomes 
are essential in terms of modern healthcare. Seeing as though it is becoming increasingly 
difficult and expensive to develop novel drug molecules (Wen and Park, 2010), more 
prominence is being given to developing novel ways of delivering existing drugs. Due to the 
reality that pharmaceutical companies are faced with increasing challenges as a result of the 
higher cost of starting up product lines and decreased market shares (Lee, 2007), there is a 
decreased accomplishment of developing novel pharmaceutical drug actives. Therefore, 
developing advanced drug delivery technologies may allow for the extension of the use of 
existing pharmaceutical drug actives. The requirement of these novel pharmaceutical 
concepts is due to the prominent therapeutic failures that occur as a result of non compliance 
of the patient to multiple drug treatment regimens. The possible motives of non compliance 
have been elucidated to be pill burden and dose-dependent side-effects that occur with 
various multi-drug treatment regimens. Difficulty comprehending drug administration 
instructions also plays a role in failed therapeutic results especially with complex drug 
regimens that require a variety of tablets to be taken at various time intervals per day. As a 
result of these short comings, health resources are wasted leading to economic 
consequences. For example non-compliance with cardiovascular and antidiabetic medication 
is a sizeable problem.  
 
Furthermore, the management of numerous infectious diseases such as Tuberculosis and 
HIV/AIDS is still limited due to poor treatment compliance (Munro et al., 2007), this adds to 
the disease burden worldwide. The discovery and establishment of novel drug delivery 
systems that work effectively and efficiently to reduce dose dependent side-effects and pill 
burden is yet to be adequately fulfilled.  
 
The crucial ambition of this research was to develop an oral triple-layered tablet system for 
the controlled zero-order delivery of any suitable therapeutic regimen, which is equipped to 
hold up to three drug actives with the focal-point honing in on the improvement of patient 
compliance and reduction of the occurrence of dose-dependent side-effects. The 
administration of one tablet once per day is understandably easier to comprehend by the 
patient than three tablets three times a day. The novelty of the proposal lies in the linear 
release of three different drugs from one TLT. This allowed for a constant amount of drug 
entering the blood stream reducing dose-dependent side-effects.  
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In vitro studies involved preliminary experimentation whereby novel polymers were 
synthesized and employed as drug matrices. TLT formulations were subjected to extensive 
in vitro release studies to assess the capability of providing zero-order release of all three 
water-soluble drugs. BHN as a measure of matrix hardness was another essential factor in 
determining the robustness of the TLT.  
 
The Box-Behnken design was utilized in the TLT optimization process which focused on the 
drug release characteristics. Rate constants (k values) and correlation coefficients (R2 
values) were employed as the measured responses for 17 formulations. A solitary 
formulation was selected as the optimized formulation and the release profile of the three 
drugs were corroborated.   
 
In addition, a novel drug regimen that comprised atenolol (50mg), simvastatin (40mg) and 
aspirin (100mg) was applied to the optimized TLT; in vitro drug release of this regimen was 
also assessed to determine the flexibility of the TLT to provide zero-order release of a 
cardiovascular therapeutic drug combination.  
 
Furthermore, in vivo studies were performed on the optimized TLT. The TLT was 
administered to pigs and drug-release profiles were generated according to the concentration 
of drugs in plasma at predetermined time intervals. Results from in vivo studies showed a 
definite difference of plasma profiles between conventional tablets Tenormin®, DISPRIN CV® 
and Adco-simvastatin 40 and the optimized TLT formulation. The release was markedly 
noted to be more controlled and provided near zero-order to zero-order release. Thus, the 
TLT provided some degree of sustained and controlled release of the therapeutic regimen.  
 
The TLT developed in the study showed flexibility in providing zero-order release of different 
drugs. Although a cardiovascular regimen was employed, the TLT is not limited to this. It may 
be applied to the delivery of various and appropriate disease treatment regimens. The oral 
administration of the TLT may therefore reduce the pill burden and dose-dependent side-
effects of different treatment regimens. 
 
7.2. Recommendations  
 
With oral drug delivery being the least invasive mode of therapy, it can be concluded that 
more comprehensive research should be conducted to develop more efficient and applicable 
oral drug delivery systems utilizing existing drugs. Improved and dynamic drug delivery 
systems may prove to have a significant positive effect on patient therapeutic outcomes. The 
synthesis of “smart” polymers as drug matrices could be further analyzed and optimized to 
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decrease research time while increasing efficiency. The application of a gastro-retentive 
aspect to the TLT may prove to be advantageous for controlled release of Narrow Absorption 
Window drugs. This may also pose an advantage in providing controlled release of drugs for 
an extended period greater than 24 hours. 
 
Although the in vivo animal study model proved to be efficient, it may be limited in the results 
that are computed from it. The reason for this may be the altered behavior of the TLT in a pig 
model according to a specific diet. Also, the molecular absorption of drug molecules from the 
gastrointestinal tract into plasma may need to be adequately investigated which is difficult in 
such a setting. Further emphasis should therefore be given to comprehensive in vivo 
analysis. Research should aim to develop modern techniques that allow for uncomplicated 
administration with minimal to no distress to the animals. Analytical techniques to best 
identify in vivo pharmacokinetic behavior and imaging may also be investigated and 
improved.  
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